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ABSTRACT
Childhood cancer survivors are at risk for long-term neurocognitive morbidities.
Current research has only recently begun to examine how these neurocognitive late effects
translate into impairments across important aspects of daily living. Additionally, research
remains in its early stages of identifying risk factors associated with neurocognitive and
broad functional impairments. The current study explores a proposed model of
neurocognitive late effects by examining the relationship between neurocognitive deficits and
broad functional impairment in cancer survivors relative to healthy controls. The current
study also explores the contribution of associated risk factors including treatment severity
and time since treatment among cancer survivors and long-term stress reactivity among both
cancer survivors and healthy controls. Cancer survivors and healthy controls were between
the ages of five and eighteen years. Hair samples were collected from the children to assess
cortisol, a measure of long-term stress reactivity. Parents completed a functional impairment
questionnaire while a brief neurocognitive exam was administered to the children. Results
found no differences in neurocognitive performance or levels of functional impairment in
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cancer survivors relative to healthy controls; however, verbal reasoning was found to be a
more robust predictor of functional impairment (FI) in cancer survivors in comparison to
healthy controls. Importantly, and calling into question the validity of FI measurement in
children, approximately half of both cancer survivors and health controls reported clinically
significant levels of FI. This was in excess of that reported by parents. Additionally, cortisol
levels were found to differentially predict neurocognitive performance in cancer survivors
relative to healthy controls. Taken together, these findings suggest that verbal reasoning
predicts functional impairment, but only in cancer survivors. Additional risk factors require
more exploration in future research.
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Introduction
Cancer represents one of the leading causes of death in children, accounting for eight
percent of childhood mortalities (Institute of Medicine, 2003). Although cancer mortality
rates continue to be a major concern, significant improvements in survival rates have been
demonstrated over time. In the past 23 years alone, mortality rates for pediatric cancer have
decreased by 50 percent and current 5-year survival rates have been estimated to be between
70 and 80 percent (Institute of Medicine, 2003).
The remarkable progress in survival rates can be attributed to the considerable
advancements in treatment strategies, which include chemotherapy, radiation, and surgery.
These treatment advances have resulted in a growing population of pediatric cancer
“survivors.” The concept of “survivor” first emerged in the 1970s and was used to describe
any individual with cancer alive at any point from the diagnosis forward (Meadows, 2003;
Institute of Medicine, 2003). Due to modern therapeutic approaches, more and more children
are surviving into adulthood and are receiving the status of long-term survivor (e.g., 5 years
post-treatment). While aggressive treatments have helped contribute to this growing
population of survivors, these treatments also come with a cost, as survivors are at risk for
additional long-term morbidities (Dickerman, 2007; Patenaude & Kupst, 2005). These
morbidities are referred to as late effects and are more formally defined as any adverse
outcome related to the disease process, treatment, or both, occurring more than six months
after the completion of treatment (Meadows, 2003; Pentheroudakis & Pavlidis, 2007).
Late effects represent a significant concern for pediatric cancer survivors, as twothirds of survivors are likely to experience at least one late effect, while one-fourth of
survivors are likely to experience late effects that are severe and even life threatening
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(Institute of Medicine, 2003). These late effects can manifest as physical impairments
(Oeffinger et al., 2006) or psychological impairments. Psychological late effects have been
separated into two distinct domains including psychosocial (Patenaude & Kupst, 2005) and
neurocognitive (Moore, 2005) late effects. In regards to physical late effects, there is a large
degree of variability, as they can range from minor to severe (Meadows 2003). These late
effects can influence growth and development, fertility and reproduction, as well as vital
organ functioning such as cardiac, pulmonary, renal, endocrine, and gastrointestinal function
(Meadows, 2003).
Psychosocial late effects have been well documented in pediatric cancer survivors.
While these late effects are highly variable, common manifestations include behavior
problems, decreased social competence, and engagement in peer activities, depression,
anxiety, and post-traumatic stress symptoms (Schultz et al., 2007; Stam, Grootenhuis, &
Last, 2001). Neurocognitive late effects have also been found to be highly variable, with
impairments across a broad range of areas. These include attention, executive functioning,
memory, information processing speed, visual-spatial skills, and general intellectual
functioning (Moore, 2005; Moore, Ater, & Copeland, 1992; Mulhern, Wasserman,
Fairclough, & Ochs, 1988).
Neurocognitive Deficits Among Pediatric Cancer Survivors
Neurocognitive impairment is one of the foremost psychological late effects
experienced by pediatric cancer survivors and it has been estimated to impact as many as
sixty percent of survivors (Nathan et al., 2007). The manifestation of these deficits, similar to
other late effects, is somewhat variable. Previous research has documented impairments
across the domains of attention, executive functioning, processing speed, working memory,
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visuospatial skills, and fine motor skills (Askins & Moore, 2008; Nathan et al., 2007).
Declines in general intellectual functioning, as well as academic achievement, have also been
documented (Campbell et al., 2007; Montour-Proulx et al., 2005).
Despite this heterogeneous presentation of cognitive impairment, research has
consistently identified executive functioning and global intellectual functioning, as two
domains that are particularly vulnerable to impairment (Campbell et al., 2007; Ellenberg et
al., 2009; Montour-Proulx et al., 2005; Mulhern, Fairclough, & Ochs,1991; Nathan et al.,
2007;)
Intellectual functioning. Previous research suggests that pediatric cancer survivors
are vulnerable to impairments in general intellectual functioning. Reddick and colleagues
(2003) found evidence of intellectual impairments in survivors of brain tumors. A recent
meta-analysis (Robinson et al., 2010) reported similar findings. A study conducted by
Brinkman and colleagues (2012) also found that brain tumor survivors demonstrated
intellectual functioning (i.e., IQ) scores one standard deviation below the normative
population. Deficits in general intellectual functioning have also been identified in other
cancer diagnoses such as leukemia/lymphoma. For example, a study examining general
intellectual functioning in both pediatric cancer survivors of acute lymphoblastic leukemia
(ALL) compared to healthy controls found statistically significant lower IQ scores among
pediatric cancer survivors (Anderson et al., 1994). Montour-Proulx and colleagues (2005)
also found evidence for mild intellectual deficits in childhood cancer survivors, as their
scores fell consistently below the normative population by one standard deviation. Other
studies suggest that while survivors demonstrate intellectual functioning within the average
range, their scores are still lower than healthy controls (Lofstad et al., 2009).
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While many studies provide evidence in favor intellectual impairments in pediatric
cancer survivors, there are a few studies that have not replicated these findings. For example,
Copeland and colleagues (1996) examined intellectual functioning and found no consistent
evidence for intellectual decline following cancer treatment. In a study conducted by Espy
and colleagues (2001), children diagnosed with leukemia were evaluated two, three, and four
years post diagnosis. Growth curve analysis found no evidence of declines in intellectual
functioning. However, despite some inconsistencies among studies, general IQ deficits are
frequently documented in pediatric cancer survivors. The discrepant research findings may
be attributed, in part, to the multiplicity of factors that influence how neurocognitive late
effects manifest, including disease and treatment related variables, how such late effects are
evaluated, as well as individual difference variables. These discrepant findings also suggest
that risk factors associated with more pronounced IQ deficits are not well enough understood.
Executive functioning. Executive functioning (EF) represents a complex cognitive
construct with some disagreement with regard to the primary executive abilities, how they
are organized, underlying neuroanatomy, as well as proper measurement. Despite this lack of
clarity, EF has previously been conceptualized as those abilities that reflect a capacity to
engage in goal oriented behavior (Lezak et al., 2012). Specific subdomains that have been
identified as relevant components of executive functioning include attention, fluency,
working memory, set shifting/task switching, and inhibitory control (Kramer et al., 2014).
The prefrontal cortex has been implicated in these component processes (Wolfe et al., 2012).
Additionally, white matter volumes, particularly in the frontal regions, have also been
associated with executive functioning abilities. Research suggests that an increase in

5
myelination within the frontal lobes co-occurs with the development and solidification of EF
abilities (Wolfe et al. 2012).
A significant body of literature has examined executive functioning in pediatric
cancer survivors. Findings consistently reveal that survivors demonstrate impairments in
executive functioning abilities such as processing speed, working memory, attention, and
task switching (Anderson, Smibert, Ekert, & Godber, 1994; Ness et al., 2008). Brinkman and
colleagues (2012) found that 75 percent of medulloblastoma survivors were impaired on at
least one measure of executive function, while Maddrey and colleagues (2005) found that 78
percent of medulloblastoma survivors demonstrated impairments in sustained attention, and
90 percent demonstrated impairments on motor-based attention tasks. Impairments in
executive functioning have also been documented among survivors with other cancer
diagnoses such as leukemia. In pediatric survivors of ALL, significant executive functioning
deficits have been observed, such as deficits in working memory, attention/orientation, and
processing speed. A meta-analysis conducted by Peterson and colleagues (2008) found that
survivors of ALL demonstrated significant impairments in processing speed, working
memory, and executive functioning in the form of task switch (e.g. Trails B). Another metaanalysis documented similar impairments in attention, processing speed, and other areas of
executive functioning (Campbell et al., 2007).
Although a common profile of deficits has been identified (i.e. deficits in attention,
executive functioning, and general intellectual functioning), observed impairments still
remain highly variable, and a review of the literature has revealed notable inconsistencies.
The variability in research findings is partly due to the variability in research methodology.
For example, many studies do not use a comparison group (e.g., healthy controls), and
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instead make comparisons based on normative population values. Other studies use healthy
control populations for comparisons, while others use sibling controls. Additionally, there
are very few studies that employ a longitudinal approach that also includes premorbid
cognitive functioning prior to diagnosis and treatment.
Additionally, the variability in neurocognitive performance is also due to the
multiplicity of factors that influence how neurocognitive late effects manifest. Previous
research has identified disease and treatment related risk factors as well as patient related risk
factors, which may be relevant to understanding outcome heterogeneity.
Risk Factors for Neurocognitive Impairment
Specific risk factors have been proposed in an attempt to explain neurocognitive
deficits in pediatric cancer survivors. Factors that have been identified include disease and
treatment related variables, which appear to have influence over and above psychosocial and
environmental factors.
Treatment. Previous research has identified disease and treatment related factors as
potential contributors to the development and severity of general intellectual and executive
function deficits. These studies have demonstrated that such deficits more commonly
manifest with a diagnosis of leukemia or central nervous system (CNS) tumor, relative to
other diagnostic groups (Campbell et al., 2007). The specific vulnerability of leukemia and
brain tumor survivors is likely due to the similarities across treatment approaches for both
groups. For example, aggressive CNS directed treatments are applied to both leukemia and
brain tumors and represent a significant assault on the CNS. CNS directed treatments that are
commonly associated with neurocognitive impairment include chemotherapy in the form of
intrathecal (IT) methotrexate and cranial radiation therapy (CRT).
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Cranial radiation therapy. Cranial radiation therapy (CRT) represents a common
treatment used to treat both leukemia and brain tumors. The use of cranial radiation therapy
has been implicated in the development of executive function impairments (Moore, 2005).
For example, Moore, Ater, and Copeland (1992) examined the effects of CRT on
neurocognitive performance in a group of child survivors of brain tumors. Results indicated
that children treated with CRT demonstrated significantly lower performances on measures
of attention, memory, motor, and visuo-spatial skills relative to those children who did not
receive CRT. Anderson and colleagues (1994) compared neurocognitive performances across
three groups: children who received CRT, children who did not receive CRT, and healthy
controls. Results found that irradiated children performed more poorly on tests of intellectual
functioning than non-irradiated children and healthy controls. The most pronounced deficits
were found in verbal and attentional abilities.
There is also evidence to suggest that CRT disrupts and damages the structural
integrity of the developing brain. Cortical atrophy, vascular damage, and
leukoencephalopathy have all been associated with the use of CRT (Mulhern 1994), and
approximately 50 percent of patients treated with CRT show changes in white matter (Askins
& Moore 2008). Additionally, this white matter damage is irreversible and does not diminish
with time. Reddick and colleagues (2003) found that patients treated with CRT demonstrated
a significant decrease in normal-appearing white matter volume when compared to untreated
individuals of the same age. The finding that CRT is associated with structural abnormalities
and reductions in normal-appearing white matter has been replicated across additional studies
(Mulhern et al., 1999; Reddick et al 2000; Reddick 2006).
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Additional research has found a direct link between CRT induced structural damage
and subsequent neurocognitive deficits. In a group of pediatric cancer survivors treated with
CRT, Reddick and colleagues (2003) examined the relationship between changes in normalappearing white matter (NAWM) and neurocognitive deficits such as general intellectual
deficits, memory deficits, and attention deficits. Results found that decreases in normalappearing white matter (NAWM) volumes were significantly associated with more
pronounced deficits in attention. In a similar study, there was evidence for a significant
relationship between smaller volumes of white matter and impairments in attention,
intelligence, and academic achievement (Reddick 2006). Iuvone and colleagues (2002) also
found a similar relationship between white matter abnormalities and neurocognitive
performance in child cancer survivors treated with CRT.
Chemotherapy. Due to the long-term toxicity of CRT and the problematic outcomes
associated with its use, most treatment protocols reserve CRT for high-risk leukemia patients
and patients with brain tumors. With the declining use of high dose CRT, CNS prophylaxis
treatments have begun to use chemotherapy, more specifically, intrathecal methotrexate (IT
MTX). The delivery of chemotherapy intrathecally allows it to permeate the blood-brain
barrier, and thus allowing the treatment to target the CNS. The use of CNS directed
chemotherapy has historically been preferred over CRT, as it was originally thought to be
benign in terms of long-term neurocognitive impairments. Despite this, an impressive body
of literature seems to suggest CNS-directed chemotherapy is not quite so benign. In a review
of the literature, Moleski (2000) found that approximately two thirds of research on the
effects of CNS-directed chemotherapy documents some type of decline in general intellectual
functioning, while one fourth of the research documented deficits in at least one area of
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neurocognitive functioning including executive functioning. Most research surrounding the
deleterious effect of chemotherapy has examined one specific chemotherapy agent, itrathecal
methotrexate (IT MTX). Children treated with this type of CNS directed chemotherapy have
experienced deficits in general executive function, as well as attention and processing speed
(Moleski, 2000; Peterson et al., 2008).
Similar to CRT, CNS-directed chemotherapy has also been associated with structural
damage within the CNS. More specifically, IT MTX has been implicated in structural
damages due to its neurotoxicity. Iuvone and colleagues (2002) found intracerebral
calcifications in 24 percent of child survivors of ALL who were treated with IT MTX.
Damages and disruptions in normal-appearing white matter have also been associated with
the use of IT MTX, as two thirds of children who received IT MTX demonstrated white
matter alterations via neuroimaging (Moleski, 2000). Additional structural damages have
been associated with the use of IT MTX including leukoencephalopathy, intracerebral
calcifications, and cortical atrophy (Moleski, 2000).
A relationship between chemotherapy induced structural changes and neurocognitive
deficits has also been established. Reddick and colleagues (2006) examined the relationship
between impairments in neurocognitive performance and normal-appearing white matter
following chemotherapy. Results indicated that children treated with chemotherapy still
demonstrated significant reductions in normal-appearing white matter relative to healthy
controls. These smaller volumes were significantly associated with more pronounced deficits
in attention, intellectual functioning, and academic achievement. Carey and colleagues
(2008) used voxel based morphology (VBM) to measure regional differences in brain
functioning as a result of CNS directed chemotherapy. Results found two specific regions of
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reduced white matter within the right frontal lobes of survivors, which were not evident in
controls. Survivors also demonstrated poorer performance on measures of attention, visual
construction abilities, mental flexibility, and math achievement.
Neurosurgery. While commonly implemented cancer treatments include
chemotherapy and radiation therapy, children diagnosed with brain tumors often undergo
initial treatment with neurosurgical intervention. Neurosurgical resection represents a
particularly aggressive assault on the brain. As such, neurosurgical intervention has been
associated with immediate and often long-term consequences to children’s CNS. Carpentieri
and colleagues (2008) found that patients with localized brain tumors treated with surgery
only demonstrated deficits on neurocognitive measures of motor output, verbal memory, and
visuospatial organization. Askins and Moore (2008) suggest that such late effects may occur
as a result of the neurosurgical resection of tumors that encroach upon critical areas of the
brain involved with attention and executive functioning. As such, it is not just the removal
process, but also the actual location of the tumor that plays a critical role in the degree to
which neurocognitive deficits are expressed.
Treatment dosage. CRT, CNS directed chemotherapy, and neurosurgery are
treatments that have been associated with structural changes within the brain, as well as
impairments in executive functioning and global intellectual functioning. Treatment dose has
also been found to play a significant role in the manifestation of these deficits. For example,
higher doses of CRT have been associated with more pronounced neurocognitive deficits,
including executive function and global intellectual deficits (Moore, 2005). There is also
evidence that structural damage resulting from CRT is moderated by treatment dosage, as
brain tumor survivors have evidenced slower rates of white matter loss when exposed to
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lower doses of radiation (Reddick et al., 2000). Evidence of a dose response relationship has
been replicated across additional studies (Armstrong et al., 2010; Mulhern, Fairclough,
Smith, & Douglas, 1992). CNS directed chemotherapy has also demonstrated a dose
response relationship (Iuvone et al., 2002; Montour-Proulx et al., 2005), such that higher
doses have been associated with more severe deficits.
Additional research suggests that the combined use of both CRT and IT MTX
heightens the iatrogenic effects of either of these treatments when used in isolation. The
relationship between treatment intensity and severity of neurocognitive impairment can be
explained in terms of the aggregate assault on the CNS. Lower doses of CNS directed
treatment result in lower neurotoxicity, less structural damage, and consequently, fewer
deficits. Higher doses of CNS directed treatments result in higher neurotoxicity and
consequently more structural damage and neurocognitive deficits. Additionally, the
combined use of CRT and IT MTX has been suggested to interact synergistically, enhancing
the effect on the CNS. More specifically, CRT is thought to induce alterations in the blood
brain barrier, allowing IT MTX to permeate the blood brain barrier with greater ease and
frequency. The outcome of this process is an intensification of the neurotoxic effects of IT
MTX (Moleski, 2000). In general, the use of higher doses, as well the combination of
treatment modalities, results in more severe manifestations of general intellectual and
executive function deficits.
Thus, a wide body of research clearly reveals a significant relationship between
cancer treatment (e.g., CRT and CNS-directed chemotherapy), reductions in normalappearing white matter, and deficits in global intellectual functioning, as well as executive
functioning. Children may be particularly vulnerable to this process, as myelination
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continues throughout adolescence and young adulthood, specifically within the frontal lobes
(Wolfe et al. 2012), thus resulting in pronounced neurocognitive deficits.
Patient related factors. Biological variables such as sex and age have also been
found to influence the severity of neurocognitive deficits (Askins and Moore; 2008; Moleski
2000; Nathan et al. 2007). For example, girls are at higher risk of neurocognitive impairment
than boys (Christie et al 1995; Nathan et al 2007). Von der Weid and colleagues (2003)
found that female survivors scored, on average, ten points lower on measures of intellectual
functioning than males. Similar findings have been consistently replicated across additional
studies (Ellenberg et al 2009; Peterson et al. 2008; Waber et al 1990). The heighted
vulnerability of females remains consistent regardless of treatment modality (Brown et al.
1998; Mulhern, Fairclough, and Ochs, 1991).
The severity of neurocognitive impairment also appears to be negatively correlated
with age such that younger children are at heightened risk for experiencing more severe
neurocognitive deficits. (Moore 2005). Children treated with CRT at a younger age have
been found to demonstrate more pronounced deficits in intellectual functioning, whereas
children treated at an older age do not demonstrate such dramatic deficits (Mulhern et al
1998; Nathan et al. 2007). Mulhern and colleagues (1992) found that young children treated
with CRT demonstrated a 14-point difference in IQ score relative to older children. Other
studies have reported similar findings (Kadan-Lottick et al. 2010).
Models of Neurocognitive Late Effects
Based on these findings, three separate models of neurocognitive deficits in pediatric
cancer survivors have been proposed. In the first model, proposed by Reddick and colleagues
(2003), neurocognitive deficits are explained as a function of decreases in normal-appearing
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white matter in frontal regions of the brain. Reductions in normal appearing white matter are
used to explain impairments in specific attentional abilities, which then impact IQ and
academic achievement. Reddick and colleagues also proposed a direct link between attention
and academic achievement. While this model was the first to highlight the neurobiological
substrates of neurocognitive late effects, it failed to include additional measures of executive
functioning, as well as treatment and patient related variables.
Palmer and colleagues (2008) introduced another model and included patient and
treatment related variables. This model proposed a relationship between disease and
treatment related variables and specific components of EF (e.g., processing speed, attention,
and working memory). A relationship was also proposed between impairments in EF and
impairments in global intellectual functioning and academic achievement. Palmer and
colleagues also included the contribution of patient related variables such as age and sex.
Wolfe and colleagues (2012) criticized this model for overlooking the contribution of
underlying white matter changes, as well as additional components of EF including planning
and metacognition.
As a result of these limitations, Wolfe and colleagues (2012) proposed their own
comprehensive model, which included patient and treatment related factors (e.g., sex, age,
and treatment), neurocognitive factors (e.g., EF), as well as neuroanatomical factors (e.g.,
changes in normal-appearing white matter). While previous models of neurocognitive
impairment in cancer survivors have provided a strong foundation for understanding these
late effects, as well as underlying etiology, these models remain limited in scope: while
previous models have emphasized the neurobiological substrates of neurocognitive
impairment, the have overlooked the functional impact of these deficits.
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Functional impairment. Extant research has provided important information
regarding specific types of late effects experienced by pediatric cancer survivors. However,
very little is known regarding the severity of these late effects and how they disrupt
children’s day-to-day functioning. Functional impairment represents an emerging construct
within pediatric health, as it provides a benchmark beyond isolated deficits observed in
neuropsychological or psychosocial domains. The importance of functional impairment in
the context of children’s physical and psychological health has only recently emerged as a
focus of research (Palermo et al., 2008). In 1980 the World Health Organization published
the International Classification of Impairments, Disabilities, and Handicaps (ICIDH) which,
for the first time, highlighted the consequences of the disease in terms of overall functioning.
In other words, this new classification system helped shift the focus from cause to impact of
disease on day-to-day functioning (World Health Organization, 1980).
For children, functional impairment refers to the ways in which a constellation of
symptoms interfere with and reduce performance within important aspects of the child’s life
(Rapee, Bőgels, van der Sluis, Craske, & Ollendick, 2012). In this regard, the importance of
functional impairment lies in its ability to capture activities that are particularly salient to the
child’s life. Three major domains in which daily functioning may be disrupted include:
interpersonal relations, school/work functioning, and self-care/self-fulfillment (Bird et al.,
2005). Previous research has indicated that while a significant relationship exists between
isolated psychological symptoms and broad functional impairment, the relationship is not
perfect (Rapee et al., 2012). These findings suggest that while there is a relationship between
symptoms and impairment, functional impairment represents an independent construct and
should be measured in addition to specific psychological symptoms.
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There are two major advantages to examining functional impairment in pediatric
cancer survivors. First, information regarding multiple domains of deficits, such as physical,
social, and personal are included. This type of assessment moves beyond the simple
examination of isolated domains (Palermo et al., 2008), such as anxiety, depression,
cognitive impairments, or social skills, and instead provides information regarding how a
broad array of deficits interact and impede day-to-day activities. In other words, functional
impairment encompasses the wide range of psychosocial deficits that manifest in pediatric
cancer survivors. Second, measuring functional impairment provides clinically relevant
information by indicating the severity of impairment and whether it demands clinical
attention.
Although functional impairment has previously been linked to children with traumatic
brain injury, Attention Deficit Hyperactivity Disorder, and other mental health problems (Fay
et al., 2009; Huppert, Simpson, Nissenson, Liebowitz, & Foa, 2009; Lollar, 2008; Wille,
Bettge, Wittchen, Ravens-Sieberer, & group, 2008), it has only begun to be examined in
relation to the pediatric cancer experience. There is some preliminary evidence suggesting
that pediatric cancer survivors do indeed suffer functional deficits. Hudson and colleagues
(2003) examined functional status in a group of pediatric cancer survivors and found that
survivors were significantly more likely to demonstrate functional deficits, such as needing
help with personal care and routine daily rituals, and difficulty keeping and holding a job.
Pediatric cancer survivors have also demonstrated difficulties with scholastic achievement
and have been found to be significantly less likely to complete high school when compared
to healthy controls (Mitby et al., 2003). Additionally, a study from the Childhood Cancer
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Survivor Study (CSSS) reported that survivors were at higher risk for later employment
difficulties and were more likely to be unemployed (Pang et al., 2008).
Quality of life (QOL) represents a construct similar to functional impairment in that it
attempts to move beyond isolated domains in order to capture a comprehensive and holistic
picture of the child’s life. The World Health Organization (1948) defines QOL as a
multidimensional construct encompassing physical, mental, and social well-being. Zeltzer
and colleagues (2008) examined health related quality of life (HRQOL) in a group of cancer
survivors and found survivors demonstrated poorer HRQOL relative to population norms.
Additional studies have found similar results (Meeske et al., 2007; Waters, Sherman,
Galaburda, & Denenberg, 1997). In sum, preliminary evidence suggests the presence of
clinically significant functional impairments in pediatric cancer survivors. However, to date
no research has comprehensively assessed functional impairment and determined whether
rates of functional impairment are significantly different in pediatric cancer survivors relative
to a normative population.
Neurocognitive deficits and functional impairment. Executive functions are
necessary for responding adaptively to novel situations and they also form the basis of many
cognitive, emotional, and social skills (Lezak, Howieson, and Loring, 2004). Executive
functioning has been implicated in broad functional outcomes such as school readiness
(Blair, 2002), academic achievement (Espy et al., 2004), theory of mind, and social
competence (Hughes, Dunn, & White, 1998). Children with Attention Deficit Hyperactivity
Disorder (ADHD), which is characterized by deficits in executive functioning, has been
shown to demonstrate poorer functional outcomes in the form of lower educational, social,
and occupational outcomes (Shaw et al., 2012).
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The relationship between executive functioning and more broad functional outcomes
has also received some attention within pediatric cancer populations. Campbell and
colleagues (2009) examined the impact of executive functioning domains (working memory,
inhibition, cognitive flexibility, and self-monitory) on coping strategies and broad behavioral
outcomes. Results indicated that performance on executive functioning tasks was related to
coping strategies, as well as emotional and behavioral problems in pediatric survivors of
ALL. Additional research has suggested that measures of selective attention are related to
health related quality of life (Penn et al., 2010). A study conducted by Ellenberg and
colleagues (2009) found that, in a group of cancer survivors, impairments in task efficiency,
emotion regulation, organization, and memory were associated with lower socioeconomic
achievement. Lower socioeconomic achievement was defined as lower education attainment,
less household income, less full time employment, and fewer marriages. Reeves and
colleagues (2006) found that impairments in attention were related to poor academic
achievement in math and reading. Taken together, preliminary research provides compelling
evidence suggesting that impairments in executive functioning might impact broader
functional domains including academic achievement, social and emotional competence, and
socioeconomic achievement; however, additional research is needed to provide further
clarify the relationship.
In sum, pediatric cancer survivors are at heightened risk for experiencing impairments
in general intellectual and executive functioning. While previous research has exposed a
relationship between executive functioning deficits and more global functional impairments,
this relationship has not been adequately characterized within pediatric cancer populations,
and the functional impact of neurocognitive deficits remains unclear. Despite its clinical
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relevance, previous models have not yet included the functional impact of neurocognitive
late effects. The current study sought to expand on previous models by examining the
functional impact of deficits in executive functioning and global intellectual functioning.
Associated risk factors. In addition to characterizing the functional impact of
neurocognitive deficits, the current study also sought to expand on current knowledge
regarding the neurobiological substrates of both neurocognitive late effects and functional
impairment. As noted above, previous models have highlighted the role of white matter
changes in neurocognitive deficits. Additionally, previous models have explained these
changes in terms treatment toxicity and its impact on CNS development. However, absent
from these models is the impact of adjustment factors, including chronic stress, on the
neurobiological substrates that contribute to late effects.
Chronic stress. The diagnosis and treatment of pediatric cancer is an undeniably
stressful event, involving an ongoing series of stressors. This includes the diagnosis itself,
threat of mortality, lengthy and painful treatments, as well as long-term morbidities or late
effects that persist throughout survivorship. According to Varni and Wallander (1988)
pediatric cancer represents a “chronic strain” for both children and parents. “Chronic strains”
are persistent and objective conditions that require continuous readjustments, which interfere
with role-related activities (J. W. Varni & Katz, 1997). The “chronic strain” resulting from
the pediatric cancer experience seems to impact global symptoms of stress and distress.
Previous research suggests that child survivors demonstrate greater symptoms of global
distress relative to healthy controls (Lesko, 1990; Zeltzer et al., 2008). Rodriguez and
colleagues (2012) assessed a variety of cancer-related stressors and found that changes in
functional roles were most salient stressor reported by child survivors, suggesting that a
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child’s inability to perform activities was more stressful than uncertainty surrounding the
disease.
The chronic stressors associated with the pediatric cancer experience have also been
found to manifest as more severe psychopathology. In the seminal paper by Nir (1995), it
was first observed that cancer survivors demonstrated symptoms consistent with
posttraumatic stress disorder (PTSD). However, Nir’s observations were only qualitative and
comparisons to the general population were not be made. Pelcovitz (1998), however,
explored the lifetime frequency of PTSD in cancer survivors relative to individuals with an
abuse history, as well as healthy controls. Results found significantly higher rates of lifetime
PTSD in cancer survivors compared to individuals with a history of abuse (i.e. 23 percent, 7
percent respectively). Results also indicated higher rates of current PTSD in cancer survivors
relative to those with an abuse history (i.e. 17 percent, 7 percent respectively). These rates
were also significantly higher than rates found in the normative population.
The significant environmental changes facilitated by the cancer experience as well as
the prevalence of global distress and posttraumatic stress, is particularly concerning given the
allostatic load model proposed by McEwen and Wingfield (2003). Allostatic load has been
proposed as a means of explaining the relationship between chronic stress and adverse
outcomes (Johnston-Brooks et al. 1998). According to McEwen & Wingfield (2003), the
term allostasis refers to a process by which the body “maintains stability through change.” It
is through this process that individuals are able to adapt to environmental changes and
stressors, such as a cancer diagnosis. Allostatic load then refers to the cumulative
physiological cost to the body that occurs when an individual adapts to these changes and
stressors. When an individual is exposed to a number of unpredictable events in the
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environment, such as disease, human disturbance, and social interaction, an individual’s
allostatic load can increase dramatically. When the stress is chronic, there is more strain on
the physiological system, resulting in physiological and psychological damage. (McEwen &
Sellar, 1993). Increases in allostatic load have been associated with adverse outcomes
including hypertension, hyperlipidemia, diabetes, weight gain, amenorrhea, impotence and
alterations in the immune system and brain regions (e.g. hippocampus; McEwen, 1998).
The process of maintaining stability or “allostasis” in the face of environmental
change and chronic stressors requires a significant amount of energy and effort. The primary
mediators of allostasis involve hormones of the HPA axis, such as glucocorticoids or cortisol,
which become changes as a result of this process. It has been suggested that the adverse
outcomes associated with chronic stress can be attributed to cortisol levels (Howell and
Sanchez 2011; Lupien 2001). When confronted by a stressor, the body reacts by releasing
cortisol. Cortisol represents the body’s main stress hormone and works to mobilize the
body’s resources and to provide energy in the presence of a stressor (Kudielka &
Kirschbaum, 2005). When a stressor continues to persist, the stress response fails to
terminate, which results in elevated cortisol levels circulating throughout the body.
Extant research suggests that exposure to chronic stress is associated with higher
cortisol levels. In one study, individuals exposed to chronic stress demonstrated higher
cortisol concentrations in their body relative to individuals not exposed to chronic stress
(Staufenbiel, Penninx, Spijker, Elzinga, & van Rossum, 2012). Additionally, higher cortisol
levels have been found in conditions associated with chronic stress such as chronic pain
(Vachon-Presseau et al., 2013; Van Uum et al., 2008), chronic fatigue (Torres-Harding,
2008) unemployment (Dettenborn et al., 2012; Dettenborn, Tietze, Bruckner, & Kirschbaum,
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2010), and depression (Dettenborn et al., 2011). A meta-analysis conducted by Hunter and
colleagues (2011) demonstrated that early life adversity and psychosocial stressors were
related to increases in cortisol reactivity. Higher cortisol levels have also been found in shift
workers, relative to day workers (Manenschijn, van Kruysbergen, de Jong, Koper, & van
Rossum, 2011), and in individuals who experienced major life stressors (Karlén, Ludvigsson,
Frostell, Theodorsson, & Faresjö, 2011). Low socioeconomic status (SES) is one particular
source of chronic stress that has received significant attention in terms of its relationship to
cortisol concentrations. In general, individuals with low SES report greater stressful life
events (Lupien 2001). Additionally, children with low SES have higher salivary cortisol
levels relative to children with high SES (Lupien 2001; Lupien 2005).
Only one study to date has examined the relationship between the chronic stress
associated with the pediatric cancer experience and cortisol output. Gordijn and colleagues
(2012) found that child survivors of acute lymphoblastic leukemia experienced elevated
levels of cortisol relative to healthy controls.
In sum, previous research clearly reveals a relationship between chronic stress
exposure and elevated cortisol levels. Previous research has also identified the pediatric
cancer experience as a particularly salient chronic stressor. Given these findings, it stands to
reason that the pediatric cancer experience is associated with elevated cortisol production.
This conclusion has been supported by the one study to date that has examined cortisol levels
in a pediatric cancer population.
Chronic stress and neurocognitive deficits. Cortisol levels following chronic stress
exposure have been shown to impact the structural integrity of the CNS, as well as
neurocognitive functioning. Lupien and colleagues (2005) suggest that cognitive processing
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abilities, maintained within the frontal lobes, are sensitive to acute increases in
glucocorticoids. A study conducted by Sheridan and colleagues (2012) found a relationship
between changes in salivary cortisol levels and activity in the prefrontal cortex (PFC).
Additionally, decreases in hippocampal volume have been documented in relation to chronic
stress exposure and cortisol output (Lupien et al., 2005). In a study conducted by Carrion and
colleagues (2007), posttraumatic stress symptoms and cortisol levels at baseline were found
to predict reductions in hippocampal volumes across 12 and 13 months intervals.
In addition to structural changes, cortisol levels have also been associated with
neurocognitive functioning including learning and memory (Heffelfinger 2001). It has been
suggested that young children (e.g., preschool years) may be particularly vulnerable to the
impact of cortisol, as young children are only beginning to develop these cognitive abilities
and therefore may be vulnerable to the iatrogenic effects of cortisol (Heffelfinger 2001). The
relationship between cortisol and cognitive outcomes was first demonstrated in animal
models, as Mizoguchi and colleagues (2004) found that, in rodents, glucocorticoids were
necessary for neurocognitive abilities associated with PFC activity such as working memory.
Suppression of glucocorticoids was found to impair working memory.
Additional research in child populations supports a relationship between cortisol
concentrations and neurocognitive functioning. For example, Keller and colleagues (2012)
found evidence in favor of a relationship between cortisol levels and intellectual and
academic achievement in children. Extreme levels of cortisol (e.g., high and low levels)
predicted poor neurocognitive performance while moderate levels predicted better
performances.
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Impairments in executive functioning represent a particularly salient outcome related
chronic stress exposure. Previous research has documented a relationship between
posttraumatic stress disorder, posttraumatic stress symptoms, and impairments in executive
functioning (LaGarde et al. 2010). A meta-analysis conducted by Polak and colleagues
(2012) found that patients with PTSD demonstrated more severe impairments in executive
functioning relative to patients without PTSD. This relationship may be mediated by elevated
cortisol levels that result from persistent exposure to stressors and elevated cortisol levels
have been directly associated with impairments in executive functioning (S. Lupien et al.,
1994; S. J. Lupien et al., 1999). A study conducted by Blair and colleagues (2011) found that
higher resting cortisol levels in infants were related to poorer executive functioning. Tu and
colleagues (2007) found that higher basal cortisol concentrations in infants were associated
with poor focused attention. Another study conducted by Blaire and colleagues (2005) found
that individuals who demonstrated a healthy cortisol profiles when confronted with a
moderate stress (i.e. brief increase in cortisol followed by a decrease) also demonstrated
better executive functioning. Additional studies have found a relationship between healthy
cortisol profiles and better executive functioning (Stawski et al., 2011). Berry and colleagues
(2012) found that cortisol profiles at 7, 15, and 24 months predicted executive functioning at
17 and 36 months as well as academic achievement in kindergarten.
There is also preliminary research suggesting a relationship between cortisol levels
and broader functional outcomes. Gordjin and colleagues (2012) examined the relationship
between cortisol levels and quality of life in a group of pediatric cancer survivors. Result
indicated a significant relationship between cortisol and quality of life, such that higher
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cortisol levels were associated with poorer quality of life. Higher cortisol levels have also
been associated with poor mental health in children (Essex et al. 2000)
In sum, the pediatric cancer experience represents a source that contributes to
significant chronic stress. Chronic stress, as demonstrated through cortisol levels, has been
implicated in structural changes within the CNS, as well as neurocognitive deficits, including
impairments in memory and executive functioning, as well as impairments intellectual
functioning and academic achievement. Despite such findings, previous research has not yet
examined the degree to which cortisol concentrations contribute to neurocognitive
impairments, as well as more global functional impairments, within pediatric cancer
populations. Additionally, previous research so far has not been able to determine the relative
contribution of chronic stress and treatment related factors on the manifestation of these
impairments. Figure 1 represents a theoretical model of neurocognitive deficits following the
pediatric cancer experience including associated risk factors, as well as the functional impact
of deficits. The current study sought to provide preliminary evidence for this model by first
characterizing some of the relationships highlighted in this model.
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The Current Study
Objectives
This study sought to explore and characterize relationships within the proposed
conceptual model of neurocognitive late effects by first examining the functional impact of
deficits, as well as by determining the relative contribution of associated risk factors
including treatment related variables (e.g., treatment severity and length of survivorship), and
chronic stress measured through cortisol concentrations. There were three main objectives to
this proposal: 1) determine the frequency and severity of deficits in EF, intellectual
functioning, and functional impairment in a group of pediatric cancer survivors compared to
healthy controls; 2) examine the relative contribution of child neurocognitive functioning to
functional impairment in survivors relative to controls; and 3) examine how treatment
severity, length of survivorship, and chronic stress are associated with neurocognitive and
functional endpoints.
Hypotheses
There were three main hypotheses that corresponded to the study objectives: 1)
Pediatric cancer survivors would demonstrate deficits in EF and global intellectual
functioning, as well as an increased incidence of functional impairment, relative to healthy
controls; 2) Poorer performances on neurocognitive tasks would be associated with greater
functional impairment; 3) Pediatric cancer survivors would demonstrate significantly
different cortisol levels than healthy controls, and both treatment severity and chronic stress
would be significantly related to neurocognitive and functional endpoints for cancer
survivors.
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Methods
Participants
Participants included pediatric cancer survivors, healthy controls, and parents of each
group of children. Eligibility criteria for cancer survivors included :1) ages 5 through 18; 2) a
previous cancer diagnosis; 3) at least 1 year post-treatment; and 4) ability to follow
instructions in English. Individuals were excluded from the study at the discretion of the
investigator (e.g., child had a visual impairment) and/or if they had a history of intellectual
disability (IQ<70).
Eligibility criteria for healthy controls included: 1) ages 5 through 18: and 2) ability
to follow instructions in English. Individuals were excluded from the study at the discretion
of the investigator (e.g., child had a visual impairment) or if they had a diagnosis that
interfered with cognitive or functional abilities (IQ<70). Individuals were also excluded if
they had been diagnosed with a chronic illness including severe asthma, diabetes, JRA, cystic
fibrosis etc.
Procedure
Study procedures were reviewed and approved by the University of New Mexico
Institutional Review Board.
Cancer survivors. Parents of potential participants were recruited and enrolled by a
trained research assistant during the participant’s routine clinic appointment at the University
of New Mexico Health Sciences Center, Young Enduring Survivors (YES) Clinic. A few
days prior to their clinic visit, eligible participants were identified by clinic staff as eligible,
and were contacted via a phone call by the clinic coordinator. This was a routine call that
served to confirm and remind patients of their clinic appointment. During this routine call,
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participants were introduced to the study and informed that they would have the opportunity
to participate during or after their clinic visit. Over 400 new patients have been seen at the
YES clinic since its inception in February 2005. The YES clinic sees pediatric patients
approximately three Fridays every month, where an average of four to six patients (ages 4-18
years) are examined. The current study was open for recruitment from September 2013
through June 2014 (approximately 36 weeks) allowing for a potential recruitment pool of
approximately 144 pediatric cancer survivors.
From that potential recruitment pool, 109 survivors were scheduled and presented for
their clinic appointment. Of those, 26 participants were not approached, as they did not meet
eligibility (i.e., IQ<70, Spanish speaking, not within age range). Of the 83 family dyads that
met criteria and were approached to participate, only 20 dyads agreed to participate, resulting
in a recruitment success rate of approximately 24 percent.
Healthy controls. Healthy controls were recruited via multiple sources (online ads
placed on Craigslist, flyers placed in the community, as well as word of mouth). A brief
description of the study was provided, as well as the amount of compensation for
participation. Contact information was also listed. Approximately 45 individuals volunteered
to participate in the study. Forty-one of the 45 completed all study procedures. All 45
participants who responded to study advertisements in the community met eligibility based
on a telephone screening.
Enrollment. Cancer survivors and healthy controls were scheduled for the study visit
by one of the study RAs. The procedure began with reviewing consent/assent materials with
the parent and child. Following the completion of consent materials, a hair sample was
collected from parent and child. Child and parent were then separated into different rooms to
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ensure independent responses. Immediately following hair collection, a neurocognitive and
executive function exam was administered to the child by a trained psychometrist in a private
clinic room. After completion of the neurocognitive exam, the child completed a
questionnaire assessing functional impairment. This process required approximately 60
minutes of the child’s time. At the same time, parents completed demographic
questionnaires, as well as a questionnaire regarding their child’s functional impairment.
Upon completion of the study, parents and child each received a $20 gift card as appreciation
for their participation.
Measures
Functional impairment. Functional impairment (FI) was assessed with the Brief
Impairment Scale (BIS; Bird et al., 2005). The BIS is a 23-item, parent completed assessment
that provides a global measure of impairment along three domains of functioning:
interpersonal relations, school/work functioning, and self-care/self-fulfillment. The
assessment is intended to measure the degree to which the child struggles with various
activities. Responses are on a four-point Likert scale ranging from 0 (“no problem”) to 3
(“serious problem”). The assessment is prefaced by the statement “In general, how much of a
problem do you think your child has with”. It then includes item statements such as: “Getting
involved in activities together with the rest of the family?” “Making friends?” and “Getting
schoolwork done on time?” Data were obtained from one clinical sample (outpatient mental
health clinics) and two community samples. Convergent validity was demonstrated by
significant correlations (r =-0.53, 0.52, and -0.52; p < .001) between the BIS and an
established measure of the same construct, the CGAS (Shaffer et al., 1983). The BIS has
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internal consistency with alpha ranging from .81 to .88 as well as fair to substantial test-retest
reliability.
The BIS was designed for parents to complete yet was adapted for this study to be
completed by children as the Brief Impairment Scale-Child Version. Thus we wanted to
determine the extent to which children were able to report on their own functional
impairment. The child-adapted version was based on the same four-point Likert scale as the
original version. Similar to the original, items were introduced with the statement, “In
general, how much of a problem do you think you have with.” It then included the same item
content with the language simplified, as well as examples for children to reference: Some
examples of items included “Getting involved in activities together with the rest of the
family,” “Making friends,” and “Getting schoolwork done on time.”
In the current sample, the original BIS, intended for parent completion, demonstrated
acceptable internal consistency (α=0.71). The observed factor structure was inconsistent with
the structure proposed by Bird et al. (2005). Instead of a three-factor structure, item
responses yielded a seven-factor structure, accounting for approximately 66 percent of the
variance. A three-factor solution only accounted for 41 percent of the total variance.
The Brief Impairment Scale-Child Version (BIS-CV) demonstrated acceptable
internal consistency (α=.64), which was slightly lower than what was demonstrated for
parents. The factor structure of the BIS-CV was assessed using a principal components
analysis, with varimax rotation. Findings were inconsistent with the three-factor structure
proposed by Bird et al., (2005) for the parent questionnaire, which identifies three specific
factors or areas of impairment (e.g., interpersonal functioning, school functioning, and self
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care/self-fulfillment). Results instead favored a nine-factor structure, which accounted for
approximately 72 percent of the variance.
Despite discrepancies, the original three-factor structure was maintained due to the
low sample size of the current study. Additionally the three factor structure was based on the
theoretical structure of subdomains encompassed within the broader construct of functional
impairment (e.g., interpersonal, school, self-care). These subdomains were relevant to the
study hypotheses and were therefore maintained in the proceeding analyses.
Executive function. Executive function was assessed using the NIH Examiner
(Kramer et al., 2014). The Examiner assesses multiple domains of executive functioning
including working memory, inhibition, set shifting, fluency, planning, insight, and social
cognition/behavior. The Examiner also provides an executive function composite score as
well factor scores across three sub domains: working memory, fluency, and cognitive
control. The Examiner has demonstrated good psychometric properties. All tasks had
appropriate internal consistency with alpha ranging from .64 to .98. Test-retest reliability
across the executive function composite and factor scores ranged from 0.76 to 0.94.
Convergent validity was demonstrated by significant correlations (r=-0.21, p<.001) between
the NIH examiner composite score and a measure of parent report of real world executive
function (BRIEF).
General intellectual function. General intellectual ability was assessed using the
Reynolds Intellectual Screening Test (RIST; Reynolds & Kamphaus, 2003). This is
comprised of two subtests and was administered to all children. The RIST was standardized
on 2,438 individuals in 41 states and is representative of the 2001 US Census. Reliability
coefficients range from 0.84 to 0.96. Test-retest reliability ranged from 0.79 to 0.86.

31
Correlations with the Wechsler Intelligence Scale for Children, Third Edition (WISC-III)
Full Scale IQ were 0.76. The RIST can be completed by children in less than 20 minutes.
Cortisol. Cortisol levels were obtained through children’s hair. The measurement of
cortisol through hair represents a novel, noninvasive, and standardized sampling procedure
that allows for the measurement of long-term, chronic stress, as measured in cortisol
production (Russell, Koren, Rieder, & Van Uum, 2012; Staufenbiel et al., 2012). Other
methods of cortisol measurement, such as saliva and serum samples, measure concentrations
of cortisol at a single point in time, and they offer information regarding acute changes in
cortisol production. As a result, these measures are subject to major physiological daily
fluctuations, which in turn, make the assessment of long-term chronic cortisol exposure
difficult to measure. In contrast, hair cortisol analysis captures systemic cortisol exposure
over long periods of time of up to three months. In order to collect this sample,
approximately 150 strands of hair were taken from the vertex posterior part of the head. This
portion of hair was cut with sanitized scissors as close to the scalp as possible. For the hair
sample to be accurate, three centimeters of hair was obtained. Hair dye has been shown to
change the concentration of cortisol in the hair (Sauvé, Koren, Walsh, Tokmakejian, & Van
Uum, 2007), therefore we asked each participant if his or her hair was chemically dyed. The
hair samples were stored and sent off site for analysis.
Cancer variables. Child cancer variables were collected including diagnosis and
time since treatment termination. Treatment severity was derived based on the procedure
developed by Vannatta, Gerhardt, Wells, and Noll (2007) where categorical treatment
component scores were summed to create an overall index of CNS treatment intensity.
Scores of 0 or 1 were assigned for radiation exposure (0 for no CRT, 1 if CRT was
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administered). The same coding procedure was implemented for the use of Methotrexate
(0=No, 1=Yes), chemotherapy administered intrathecally (0=No, 1=Yes), and neurosurgery
(0=No, 1=Yes). Scores then ranged from 0 through 4. Higher scores were indicative of more
severe and multimodal CNS directed treatments. Cancer survivors demonstrated a mean
treatment severity score of 1.2(1.03). This represents a relatively low treatment severity score
and suggests that, in general, this particular sample had less severe CNS-directed treatments.
On average, children in this sample received only one modality of CNS directed treatment, as
opposed to combination treatments (e.g., methotrexate, intrathecal chemotherapy, and CRT).
This is in comparison to another study that demonstrated medium to severe treatment
severity scores in over half of the sample (Vannatta et al., 2007). Lower treatment severity
scores were likely secondary to the specific cancer diagnoses that characterized this sample.
Approximately 55 percent of the sample was made up of leukemia/lymphoma diagnoses and
there were no CNS tumor survivors represented in the sample. Treatment severity did not
differ between females (M=1.02, SD=1.04) and males (M=1.38, SD=1.06), p=0.57).
Length of survivorship was also recorded and ranged from 2.58 to 10.75 years
(M=6.17, SD=2.38). Length of survivorship did not differ between males (M=6.93,
SD=2.70), and females (M=5.61, SD=2.06), p=0.24.
Demographic measures. Standard demographic measures were collected for parent
and child including age, sex, race, ethnicity, parent education, and employment status. Socio
economic status was measured using the Barratt Simplified Measure of Social Status
(BSMSS; Barratt, 2006). This measure was adapted from Hollingshead (1975), and was
designed to be a proxy for socioeconomic status, and represents one of the more common
SES measures. The measure uses both educational attainment and occupational prestige as a
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way to approximate SES. The measure accounts for marital status, student status, as well as
individuals currently retired. Scores range from 8 through 66 and higher values indicate
higher SES. Scores between 8 and 30 are considered low, while scores above 30 are
considered average (Cirino et al., 2010).
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Statistical Analyses
Descriptive statistics were calculated for all child demographic variables and child
cancer related variables. A series of independent samples t-tests were used to determine
whether there were significant differences in demographic variables (e.g., age, SES) across
cancer survivors and healthy controls. Additionally, a chi square test of independence was
used to examine differences in sex and ethnicity across cancer survivors and healthy controls.
BIS concordance rates across parent and child reports were determined using simple
Pearson bivariate correlations across BIS total score, as well as BIS sub domain scores (e.g.,
interpersonal, school, self-care). Child age was included as a covariate. A chi square test of
independence determined if child age affected concordance rates. This was done by breaking
age group into two categories (e.g., 5-11 and 12-18). Clinically significant impairment was
defined as a score equal or greater than 14 (Bird et al., 2005). Child and parent total BIS
scores were first recoded to reflect clinical caseness (>14) or nonclinical caseness (<14). Item
content and scoring remained consistent across the original BIS and BIS-CV. Given this, it
was considered appropriate to determine clinical caseness for the child version based on
criteria specified by Bird and colleagues (2005) for the original version. Finally, in order to
determine if parent-child concordance differed according to age group, a parent-child
agreement (concordance) variable was coded based on agreement between parent and child
on clinical caseness.
One-way ANOVA compared mean scores on the parent BIS to mean scores on the
BIS Child Version (BIS-CV). A chi square analysis was also used to determine significant
differences in clinical impairment. Finally, a chi square test of independence was run in order
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to determine if there was a relationship between parent-child agreement/concordance and
disease group.
Statistical Analysis for Objective One: Neurocognitive Deficits and FI
In order to determine the severity of functional impairment in cancer survivors
relative to healthy controls, an independent samples t-test compared parent and child BIS
total score in pediatric cancer survivors relative to healthy controls. Comparisons of BIS
subdomain scores (e.g., interpersonal, school, and self-care) were also executed.
Additionally, a 2x2 ANOVA explored the sex by cancer interaction effect. The first variable
was cancer status and was composed of two levels (e.g., healthy control versus cancer); the
second variable also had two levels (e.g., female, male). The dependent variable included the
BIS total score and subdomain scores for parent and child. An additional chi square test of
independence examined whether there was a significant difference in casesness across cancer
survivors relative to healthy controls. Finally, an omnibus 3x2 MANOVA determined
whether the levels of impairment across the three domains (e.g., work/school, interpersonal,
and self-care/self-fulfillment) were different in cancer survivors compared to healthy controls
(i.e., were survivors more vulnerable to experiencing a specific domain of deficit). This
analysis was conducted for BIS parent and child reports.
In order to determine the severity of neurocognitive deficits in cancer survivors
relative to healthy controls, a series of independent samples t-tests were used to compare
verbal and nonverbal intellectual functioning, as well as global intellectual functioning, in
cancer survivors compared to healthy controls. Additionally, a 2x2 ANOVA was executed in
order to determine the sex by cancer interaction effect. The first variable was cancer status,
and was composed of two levels (e.g., healthy control versus cancer survivor). The second
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variable also had two levels (e.g., female, male). This same approach was used to evaluate
differences in pediatric cancer survivors and healthy controls across performances on the
NIH Examiner tasks.
Statistical Analysis for Objective Two: Neurocognitive Functioning Predicts FI
Exploratory and preliminary simple bivariate Pearson correlations were run in order
to characterize relationships among the primary variables of interest (e.g., BIS scores, RIST
score, and NIH Examiner scores).
Multiple regression analyses, using stepwise selection was used to examine
neurocognitive predictors of child and parent report of FI collapsed across cancer survivor
and health control groups in order to first examine the main effects of neurocognitive
functioning. The contribution of child demographic factors (e.g., child age and SES) were
controlled for and included in the regression as the first block. Verbal and nonverbal
reasoning t scores from the RIST were entered as the second block. Finally, NIH Examiner
domain scores were entered as the third block. Executive functioning was entered after broad
intellectual functioning because executive functioning is considered to be a cognitive process
that supports intellectual functioning and is highly correlated; however, it remains an
independent construct with unique variance that should be considered separately. Stepwise
regression was selected as the analytic technique given the exploratory nature of the study
and recognizing the limitation that this technique capitalizes upon chance relationships.
Finally, a one-way ANCOVA examined the relationship between general intellectual
functioning and broad functional impairment across both groups. In this analysis, group was
the primary independent variable, with two levels (cancer survivor, healthy control), while
verbal and nonverbal reasoning was included as a covariates Child age and SES were also
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included in the model as covariates. The interaction between the primary independent
variable and verbal and nonverbal reasoning covariates was also included in the model. This
analysis was conducted using both parent and child BIS scores as dependent variables. A
similar second analysis was conducted using performance on the NIH Examiner tasks as
covariates, while the primary independent and dependent variables stayed constant. The
interaction term between NIH Examiner covariates and the primary independent variable was
also included in the model.
Objective Three: Treatment, Length of Survivorship, and Chronic Stress Predictors
First, descriptive statistics were calculated for treatment and illness variables
including treatment severity, length of survivorship, as well as cortisol level. Independent
samples t tests compared cortisol levels in cancer survivors relative to healthy controls,
controlling for child age and SES. A 2x2 ANOVA examined the group (cancer, healthy) by
sex (male, female) interaction on cortisol. Next, exploratory preliminary bivariate
correlations were used to characterize the relationships between cortisol, treatment severity,
length of survivorship and the primary outcomes measures of interest including
neurocognitive functioning (e.g., RIST and NIH Examiner scores) and functional impairment
(e.g., BIS parent and BIS-CV scores).
Multiple stepwise regression analyses were employed, collapsed across both groups,
with age and SES entered as covariates in the first block, and then treatment severity
(treatment severity was coded as 0 for healthy controls) and cortisol level entered in the
second block. This analysis was conducted several times using different dependent variables
including performance on executive functioning (e.g., NIH Examiner) and general
intellectual functioning measures (e.g., RIST), as well as parent and child report of functional
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impairment (e.g., BIS parent and BIS-CV). The purpose of this analysis was to determine the
main effect of cortisol on neurocognitive and functional endpoints.
Additional regression analyses were executed in order to examine the degree to which
chronic stress, as measured through cortisol, contributed to neurocognitive and functional
endpoints in addition to variance already accounted for by cancer related variables including
treatment severity and length of survivorship, specifically in cancer survivors. Again,
demographic variables including child age and SES were entered into the first block. Illness
and treatment related factors, including treatment severity and length of survivorship, were
entered in the second block. Finally, cortisol was entered as the final block.
Finally, a one-way ANCOVA examined the group (cancer vs. healthy control) by
predictor (cortisol) interaction, controlling for child age and SES. In this analysis, group was
the primary independent variable with two levels (cancer survivor, healthy control), while
cortisol was included as a covariate. The interaction term between cortisol and the primary
independent variable was also included in the model. This analysis was conducted using both
neurocognitive and functional endpoints.
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Results
Demographics
Given the relatively low rate of study participation within the cancer survivors,
additional analyses examined the possibility of a selection bias. Non-participant data was
limited to child sex, child age, and diagnosis. A chi square test of independence assessed
whether child sex was associated with study participation. Results were significant X2=5.3,
p=.021 such that boys were more likely to decline participation than girls. Additionally, an
independent samples t-test compared child age across participants and non-participants.
Results were non-significant t=-1.11, p=0.27. Finally, an additional chi square test of
independence test determined whether there was a relationship between cancer diagnosis
(e.g., CNS vs. Non-CNS cancers) and study participation. Results were non-significant,
X2=2.89, p=0.09. Follow up frequency analysis indicated that 55 percent of children who
participated in study procedures had CNS related cancers, while 44 percent of participators
had non-CNS cancers. In contrast 75 percent of non-participators had CNS related cancers
and only 29 percent of non-participators had non-CNS cancers. While this difference was not
statistically significant, more children with more severe CNS related cancers chose not to
participate. This suggests that cancer severity may have been related to participation
decisions.
A total of 20 cancer survivors and 41 healthy controls were enrolled in the study.
Descriptive statistics were calculated for all demographic variables across cancer survivors
and healthy controls. Results are presented in Table 1. There were no significant differences
in age or sex across cancer survivors and healthy controls. Additionally, the ethnic make-up
of participants was consistent across both groups. Differences in socioeconomic status (SES)
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across cancer and healthy control groups approached significance (p=0.054) and suggested
that healthy controls demonstrated slightly higher SES relative to cancer survivors.
Parent and Child Concordance on the BIS
Bivariate Pearson correlations were used to measure parent and child concordance
rates across child and parent reports of FI. For analyses on BIS concordance rates, findings
were collapsed across both groups (e.g., cancer survivors and healthy controls), as the focus
was on the psychometric properties of the measure, rather than group differences. Table 2
reveals a significant positive relationship between parent and child report of global
impairment (i.e., BIS total score), r=0.27, p=0.04. Higher levels of overall functional
impairment as reported by the child were associated with higher levels of overall impairment
per parent report. However, concordance rates across BIS subscales were somewhat
inconsistent. While there was a positive relationship between parent and child reports of
interpersonal functioning, this relationship was non-significant, r = 0.18 p=0.17. In contrast,
there was a significant positive relationship between parent and child report of school
functioning r=0.41, p=0.00. Parent and child report of self-care/self-fulfillment demonstrated
a positive and non-significant relationship, r = 0.23 p=0.09. These results suggest that parent
perceptions of child functioning are somewhat consistent with the child’s own perceptions.
Parents and children appear to agree more on broad functional limitations, as well as
impairment in the domain of school functioning, but they demonstrate less agreement on
interpersonal relationships and self-care.
Given the wide age range of participants (i.e., 5-18), the same bivariate correlations
described above were computed across parent and child BIS scores while also controlling for
child age. With regard to total BIS scores, the relationship remained positive and significant,
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and the strength of the relationship increased slightly, r=0.34, p= 0.01. The correlation
between interpersonal functioning scores became significant, r=0.31, p=0.02, as did selfcare/self-fulfillment, r=0.30, p=0.03, while school functioning remained significant, r=0.30,
p= 0.003. In sum, the relationship between parent and child report of impairment became
stronger after accounting for the additional error variance in age given the wide age
distribution. Given this, a one-way ANOVA determined whether there were mean
differences in child reports of functional impairment based on age. This was done by
breaking age into two categories (e.g., 5-11, and 12-18). Results were non-significant, F(1,
57)=1.53, p=0.22. Additionally, a chi square test of independence was used to determine if
child age affected concordance rates, again, by breaking age group into two categories.
Results were non-significant and there was no relationship between child age and parentchild agreement of impairment ratings (X2=1.11, p=0.29).
Despite a significant and positive association between parent and child BIS scores,
there were still significant differences across parent and child scores F(1, 118) =33.34,
p=0.00, Partial eta squared was equal to 0.22, which can be interpreted as a medium to large
effect. Further descriptive statistics revealed that children endorsed much higher levels of FI
(M=14.48) relative to parent reports of child impairment (M=7.53). These values include
both cancer survivors and healthy controls. Additionally, a chi square test of independence
revealed significant differences in reports of clinical caseness across parent and child report
(X2=19.73, p=0.00), such that 51 percent (n=29) of children endorsed clinically significant
levels of functional impairment while only 13 percent (n=8) of parents endorsed clinically
significant levels functional impairment in their child. Again these percentage values were
collapsed across groups (i.e., cancer survivors, healthy controls). There was agreement in
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approximately 59 percent of parent child reports (n=35). Out of the eight cases identified as
clinically significant by the parents, seven were also identified as clinically significant per
child report. Taken together, these results indicate that while there is a significant and
positive relationship in parent and child reports of child FI, children tend to endorse more
clinically significant rates of impairment relative to their parents.
Finally, concordance rates were evaluated in cancer survivors relative to healthy
controls, using a chi-square test of independence. A parent-child agreement variable was
coded based on agreement between parent and child on clinical caseness, which was defined
as a score >14 (Bird et al., 2005). Results were non-significant, and there were no differences
in parent-child concordance rates in cancer survivors as compared to healthy controls
χ2=0.40, p=0.53, and concordance rates were not affected by disease group. Further
descriptive analyses revealed that 65 percent of cancer survivor dyads demonstrated
agreement in reports of clinically significant impairment while 56 percent of healthy controls
demonstrated agreement.
Objective One: Neurocognitive Deficits and FI
The purpose of objective one was to determine the frequency and the severity of
neurocognitive deficits and functional impairments in pediatric cancer survivors relative to
healthy controls. This was accomplished by comparing parent and child report of BIS scores
across cancer survivors and healthy controls, as well as comparing performances on EF (e.g.,
NIH Examiner) and IQ (e.g., RIST) measures across cancer survivors and healthy controls.
Functional impairment. Inconsistent with the study hypothesis, cancer survivors did
not show elevated levels of functional impairment relative to healthy controls. Means and
standard deviations for the BIS and BIS-CV scores across cancer survivors and healthy
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controls, as well as significance levels, are presented in Table 3. Child sex did not moderate
the effect of cancer survivorship on functional impairment per parent report F(1,57)=0.36,
p=0.56 and child report F(1, 55)=2.07, p=0.16.
An omnibus 3x2 repeated measures MANOVA determined whether there were
differences in domains of impairment (e.g. work/school, interpersonal, and self-care/selffulfillment) across groups (e.g., cancer survivor, healthy control). Results were nonsignificant per BIS-CV F(2, 55)= 0.65, p=0.93. Results were also non-significant, F(2, 58)=
1.20, p=0.34, for parent BIS. Both cancer survivors and healthy controls endorsed similar
levels of impairment across all domains of functioning and cancer survivors were not more
vulnerable to a specific domain of impairment (e.g., school, interpersonal, self-care/selffulfillment).
An additional chi square analysis determined whether there were significant
differences in rates of clinically significant impairment (e.g., scores>14) across cancer
survivors and healthy controls. Results were not significant per BIS-CV, χ2=0.009, p=0.93, or
per BIS, χ2=0.09, p=0.76. In sum, with regard to functional impairment, cancer survivors and
their parents did not report greater impairment than healthy controls and contrary to our
initial hypothesis, cancer survivors and their parents reported rates of clinically significant
impairment comparable to healthy controls.
Intellectual functioning. Means, standard deviations, and significance levels are
presented for verbal reasoning, non-verbal reasoning, and global intellectual functioning
across cancer survivors and healthy controls in Table 4. Differences were non-significant,
and our initial hypothesis was not supported, as cancer survivors demonstrated IQ scores
comparable to healthy controls. Group means were also consistent with population norms
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and fell within one standard deviation of population values. This relationship did not change
after controlling for SES and child age. Child sex did not moderate the effect of cancer
survivorship on Verbal IQ score, F(1,57)=0.77, p=0.39, Nonverbal IQ, F(1, 57)=1.11, p=0.30
or Full Scale IQ, F(1, 57)=0.04, p=0.83.
Executive functioning. Means, standard deviations, and significance levels are
presented for all NIH Examiner scores across pediatric cancer survivors and healthy controls
in Table 5. Contrary to study hypotheses, there were no significant differences in executive
functioning across cancer survivors and healthy controls, as cancer survivors demonstrated
EF scores comparable to healthy controls. Child sex did not moderate the effect of cancer
survivorship on verbal fluency F(1, 55)=0.42, p=0.52. However, child sex significantly
moderated the effect of cancer survivorship on planning, F(1, 56)=4.58, p=0.04. This was not
in the expected direction. Male cancer survivors demonstrated lower planning scores
(M=0.38, SD=0.19) than female cancer survivors (M=0.45, SD=0.23), which is inconsistent
with previous research (Christie et al., 1995; Nathan et al., 2007). However, female healthy
controls demonstrated the lowest planning scores (M=0.34, SD=0.15). Child sex did not
significantly moderate the effect of child survivorship on sustained visual attention (e.g.,
CPT), F(1, 55)=0.14, p=0.71, working memory, F(1, 55)=0.52, p=0.42, or set shifting, F(1,
55)=0.41, p=0.84.
Objective Two: Neurocognitive Functioning Predicts FI
The purpose of objective two was to characterize the contribution of neurocognitive
deficits on functional impairment more broadly (e.g., main effects collapsed across groups),
as well as within groups (e.g., cancer survivors and healthy controls). An additional goal was
to determine if the contribution of neurocognitive functioning on FI was different in cancer
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survivors relative to healthy controls. This was accomplished by first employing exploratory
and preliminary simple bivariate correlations across neurocognitive variables and FI,
collapsed across groups, and then separately within cancer survivors. Additional multiple
regression analyses were employed to determine the degree to which neurocognitive
functioning predicted FI, more broadly (i.e., collapsed across groups). Finally, a one-way
ANCOVA was then used to determine if the relationship between neurocognitive functioning
and FI was different across groups (e.g., cancer survivors and healthy controls). These
analyses were conducted using both parent and child repots of FI as dependent variables.
Child report of FI. With regard to child report of functional impairment more
broadly (e.g., collapsed across groups), Verbal IQ was significantly related to interpersonal
functioning (r=-0.26, p=0.05), self-care/fulfillment (r=-0.39, p=0.00), and global impairment
(r=-0.38, p=0.00). This was in the expected direction and higher Verbal IQ was related to
lower impairment scores with regard to interpersonal, self, and global impairment. Full Scale
IQ was significantly related to interpersonal functioning (r=0.28, p=0.03), self-care (r=-0.30,
p=0.02), and total impairment (r=-0.36, p=0.01). These relationships were in the negative
direction and were consistent with expectation, such that greater IQ scores were associated
with lower levels of impairment. Various measures of executive functioning were also
associated with functional impairment. Verbal fluency was significantly related to selfcare/self-fulfillment (r=-0.32, p=0.03). Child planning abilities (e.g., NIH unstructured task)
was significantly associated with school functioning (r=0.31, p=0.02); however, this was not
in the expected direction. As expected, working memory was negatively associated with selfcare/self-fulfillment (r=-0.33, p=0.01); and set shifting was also negatively related to selfcare/self-fulfillment (r=-0.28, p=0.03). Table 6 includes a full correlation matrix.
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Multiple regression analyses were executed with all neurocognitive variables entered
stepwise into the model, again collapsed across groups. Because SES has previously been
shown to be associated with neurocognitive performance, preliminary bivariate correlations
determined the relationship between SES, EF, IQ, and FI. SES was significantly related to
verbal reasoning (r= 0.46, p=0.00) and full scale IQ (r =0.41, p=0.00). SES, as well as child
age, was therefore controlled for in all subsequent analyses. Results indicated that verbal
reasoning was the only significant predictor of global impairment, and accounted for 16
percent of the variance, F(1,54)=10.50, p =0.002. Verbal reasoning was also found to
significantly predict interpersonal impairment, accounting for eight percent of the variance,
F(1,54)=4.45, p=0.04. Verbal reasoning was also found to be a significant predictor of selfcare, accounting for 14 percent of the unique variance, F(1, 53)=10.18, p =0.002. With regard
to school impairment, planning, as measured through the NIH Unstructured Task accounted
for eight percent of the variance, F(1,53)=4.49, p =0.04. In sum, verbal reasoning and
planning abilities significantly predicted broad FI, as well as impairment across school, selfcare, and interpersonal domains, per child report.
Within group analyses were also executed with the sample of cancer survivors to
examine the relationship between neurocognitive functioning and FI for this group
specifically. Verbal reasoning and full scale IQ were found to demonstrate the most robust
relationship with global and school impairment. Bivariate correlations are presented in Table
7.
An additional one-way ANCOVA was used to determine if the relationship between
all neurocognitive variables and FI differed in cancer survivors compared to healthy controls.
With regard to child report of FI, there was a significant group by verbal reasoning

47
interaction F(1,41)=6.58, p= 0.01, indicating that the relationship between verbal reasoning
and child report of global impairment was different for cancer survivors relative to healthy
controls. Additional within group follow up regression analyses revealed that for cancer
survivors, verbal reasoning accounted for 36 percent of the unique variance in global
impairment, after controlling for age and SES F(1, 16) =9.49, p=0.01, b=-0.62. In healthy
controls, verbal reasoning accounted for only three percent of the unique variance in
functional impairment, which was non-significant F(1, 33)= 1.49, p=0.23, b=-0.27. This
interaction is depicted in Figure 2. There was also a significant two way interaction effect
with respect to school impairment F(1,40)=4.91, p=0.03, such that, in cancer survivors,
verbal reasoning accounted for 28 percent of the variance in school impairment. This was
significant F(1,16)=5.41, p=.02, b=-0.55. However, in healthy controls, verbal reasoning
accounted for less than one percent of the variance, which was non-significant F(1,32)=0.12,
p=0.72, b=-0.07. The interaction is shown in Figure 3.
Parent report of FI. With regard to parent report of functional impairment more
broadly (e.g., collapsed across cancer survivors and healthy controls), Full Scale IQ was
significantly related to school functioning, (r=-0.29, p=0.02). This was in the expected
direction. Additionally, a significant relationship was observed between verbal fluency and
interpersonal functioning (r=0.39, p=0.00). Verbal fluency was also significantly related to
global impairment (r=0.26, p=0.05). Child planning abilities (e.g., NIH Unstructured Task)
were significantly associated with interpersonal impairment (r=0.26, p=0.05). However,
these relationships were not in the expected direction. Table 6 includes a full correlation
matrix. Within group analyses were also executed to examine the relationship between
neurocognitive functioning and parent report of FI, specifically within the sample of cancer
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survivors. Results indicated that Full Scale IQ was significantly related to parent report of
school impairment r=-0.29, p=0.02. While verbal reasoning and planning were significantly
related to total impairment and interpersonal impairment, these relationships were not in the
expected direction. A full correlation matrix is presented in Table 7.
Following broad multiple regression analyses, including both groups (e.g., cancer
survivors and healthy controls), no neurocognitive variables were retained in the model, as
none significantly predicted parent report of global impairment, school impairment,
interpersonal impairment, or self-care.
Additional analyses using ANCOVA revealed a similar two-way interaction that was
previously demonstrated based on child reports of functional impairment. Verbal reasoning
differentially predicted global impairment in cancer survivors relative to healthy controls,
F(1, 43)=4.13, p=0.048. The same two way interaction was evident with regard to selfcare/self-fulfillment F(1, 43)=5.43, p=0.02. Additional follow up analyses, comparing
regression slopes in cancer survivors relative to healthy controls, indicated that for cancer
survivors, verbal reasoning accounted for 19 percent of the unique variance in global
impairment, after controlling for child age and SES. This was marginally significant,
F(1,16)= 4.35, p=0.05, b=-0.46. For healthy controls, verbal reasoning accounted for less
than one percent of the variance in global impairment, which was non-significant, F(1,
35)=0.02, p=0.88, b=-0.03. The interaction is plotted in Figure 4.
With regard to self-care/self-fulfillment, a similar pattern emerged. For cancer
survivors, verbal reasoning accounted for 28 percent of the variance in self-care/self
fulfillment, which was significant F(1,16)=7.00, p=0.01, b=-0.56. For healthy controls,
verbal reasoning accounted for less than one percent of the variance in self-care/self-
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fulfillment, which was non-significant, F(1, 35)=0.03, p=0.85, b=-0.04. The interaction is
plotted Figure 5. Taken together, these findings suggest that the relationship between
neurocognitive functioning and broad functional impairment was more robust in cancer
survivors relative to healthy controls, such that verbal reasoning was more predictive of FI in
cancer survivors.
Objective Three: Treatment, Survivorship Length, and Chronic Stress Predictors
The purpose of objective three was to determine the relative contribution of additional
risk factors including treatment related variables, and chronic stress, on both neurocognitive
functioning and functional impairment. To do this, first, descriptive statistics were calculated
for the primary variables of interest (e.g., treatment severity, survivorship length, and cortisol
level). Table 8 presents descriptive findings. Overall, the average treatment severity score for
cancer survivors was relatively low (M=1.21). While cancer survivors demonstrated slightly
higher cortisol levels relative to healthy controls, this difference was not significant. After
controlling for child age and SES, this relationship still remained non-significant,
F(1,43)=0.97, p=0.33. There was a main effect of child sex, F(1,41)=5.63, p=0.02, such that
males demonstrated higher cortisol levels (M=16.99, SD=8.51), than females (M=12.01,
SD=5.29); however, child sex did not moderate the relationship between survivorship status
and cortisol , F(1,41)=0.377, p=0.54.
Next, exploratory and preliminary simple bivariate correlations characterized the
relationships among cortisol levels, treatment severity, and length of survivorship, as well as
neurocognitive functioning, and functional impairment, in cancer survivors only. With regard
to cancer related variables, a significant relationship between FI and length of survivorship
was demonstrated(r=0.60, p=0.01). This relationship was in the positive direction, indicating
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longer survivorship was associated with more school impairment, per parent report.
Treatment severity was also related to cortisol levels, r=0.30, p=0.04. This positive
relationship suggested that the more severe the treatment, the higher the cortisol levels.
Multiple regression analyses were again used to examine the degree to which cancer
treatment and cortisol levels predicted both neurocognitive functioning and functional
impairment (per child and parent report), collapsed across groups (healthy controls received a
score of 0 for treatment severity, indicating no treatment). Results indicated that treatment
severity and cortisol level did not significantly predict verbal reasoning, nonverbal reasoning,
verbal fluency, planning, sustained attention, working memory, or set shifting. With regard to
FI, treatment severity and cortisol level did not significantly predict child or parent report of
FI.
Additional within group regression analyses were executed in order to examine the
degree to which chronic stress, as measured through cortisol, contributed to neurocognitive
and functional endpoints, in addition to variance already accounted for by cancer related
variables including treatment severity and length of survivorship. This analysis was
conducted for cancer survivors only. Again demographic variables including child age and
SES were entered into the first block. Illness and treatment related factors including
treatment severity and length of survivorship were entered in the second block. Finally,
cortisol was entered in the final block. With regard to neurocognitive endpoints, no variables
were retained in the model. For child and parent report of FI, no variables were retained in
the model.
A one-way ANCOVA was then used to determine if the relationship between cortisol
levels, neurocognitive functioning, and functional impairment was different in cancer
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survivors compared to healthy controls. Results indicated a significant group by cortisol
interaction for verbal reasoning F(2, 37)= 3.18, p=0.05. Follow up analyses revealed that for
cancer survivors, cortisol accounted for only six percent of the variance in verbal reasoning,
after controlling for SES and child age, which was not significant, F(1, 13)=0.95, p=0.34,
b=0.342. For healthy controls, cortisol accounted for only four percent of the variance in
verbal reasoning, after controlling for SES and child age, which was also not significant F(1,
26)=2.36, p=0.13, b=-0.22. While variance accounted for was similar across groups, slope
values were significantly different and are plotted in Figure 6. There was also a significant
group by cortisol interaction for sustained attention F(1, 36)=4.61, p=0.01. Follow up
analyses revealed for cancer survivors, cortisol level did not account for any unique variance
above what was already accounted for by child age and SES F(1,13)=0.00, p=0.97, b=0.01.
For healthy controls, cortisol accounted for three percent unique variance, which was nonsignificant, F(1,25)=1.20, p=0.28, b-0.20. The interaction is plotted in Figure 7. There was
also a significant group by cortisol interaction for set shifting, F(1, 36)=11.93, p=0.00.
Follow up analyses revealed that for cancer survivors, cortisol did not account for any unique
variance in set shifting F(1, 13)=0.00, p=0.98, b=-0.00. For healthy controls, cortisol
accounted for 10 percent unique variance F(1,13)=6.14, p=0.02, b=-0.33. The interaction is
plotted in Figure 8.
There were no significant two-way interactions for either child or parent report of FI
and cortisol did not differentially predict FI across cancer survivors relative to healthy
controls.
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Discussion
Summary of Findings
The purpose of this study was to provide preliminary evidence regarding the
relationships between neurocognitive deficits, functional impairment, and associated risk
factors (treatment severity, time since treatment, chronic stress) following the pediatric
cancer experience. The goal was not only to characterize the frequency and severity of
deficits, as has previously been done in the research, but to also examine the functional
impact of deficits across salient daily activities in school, interpersonal, and self-care/selfsatisfaction domains. An additional goal was to identify the relative contribution of
associated risk factors including treatment severity and chronic stress.
Objective one: Neurocognitive deficits and FI. Broadly speaking, there has been
limited research examining the overall functional impact of neurocognitive late effects in
pediatric populations. One particular barrier involves a lack of validated measures assessing
functional impairment. A previous study conducted by the primary author (Hile et al., 2014)
attempted to examine the functional impact of neurocognitive late effects using the Brief
Impairment Scale (Bird et al., 2005). However, study methods were limited by a potential
confound, as parent reports of impairment were significantly related to parental stress levels.
This suggested a potential negative bias in which parents experiencing high levels of stress
were more likely to endorse higher levels of impairment in their children. It was unclear as to
whether this reflected true levels of impairment or just a negative response bias. In order to
control for this potential confound and obtain a more valid estimate of functional impairment,
the current study also required that children report on their own functioning and the Brief
Impairment Scale was adapted for children (e.g., BIS-CV).
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Given the use of both measures, the concordance rate between the two was examined.
In general, there was a significant positive correlation across parent and child reports of
impairment. Higher reports of impairment as reported by the children were related to higher
reports of impairment as reported by the parent. This is consistent with previous findings on
concordance between parent and child reports (Rodenberry and Renk, 2007). Similar
concordance rates were also found across the specific subdomains of impairment (e.g.,
school, interpersonal, self-care). Child age did not moderate the concordance rates, as
concordance rates remained consistent regardless of whether the child reporting was younger
(e.g., <12 years) or older (e.g., >12 years). Additionally, concordance rates across parent and
child reports remained consistent regardless of whether the child was a cancer survivor or
healthy control.
Despite a significant and positive relationship between parent and child reports of
impairment, children endorsed significantly higher levels of impairment relative to parent
reports. A previous study examining concordance rates in parent and child reports of quality
of life in cancer survivors also found similarly low concordance levels (Rodenberry and
Renk, 2007); however, these results also found that parents tended to overestimate the
psychosocial difficulties relative to child reports. The current study demonstrated opposite
findings, with children reporting more impairments than their parents. This finding was
evidenced across both cancer survivors and healthy controls. When survivorship status was
specifically examined, it did not moderate concordance rates. In sum, there was a small but
significant correlation between parent and child reports of functional impairment; however,
children, regardless of age or group, tended to endorse higher rates of impairment relative to
their parents.
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Given the discrepancy between parent and child reports of functional impairment,
both respondents (e.g., parent and child) were included when examining the degree of FI in
cancer survivors relative to healthy controls.
Contrary to our hypotheses, cancer survivors did not demonstrate increased rates of
functional impairment relative to healthy controls. This was true for both parent and child
reports of impairment. There was also no difference in the rates of clinically significant
impairment or “caseness” in cancer survivors relative to healthy controls. Additionally,
cancer survivors were not more vulnerable to any specific domain of impairment (e.g.,
school, interpersonal, and self-care). Taken together, this suggests that both cancer survivors
and healthy controls report similar levels of impairment. The cancer experience does not
appear to confer additional risk for impairment, as measured in the current study, in salient
daily activities across school, interpersonal, and self-care domains.
A previous study conducted by the primary author (Hile et. al., 2014) found that
approximately 26 percent of cancer survivors demonstrated clinically significant levels of
Functional Impairment, as endorsed by primary caregivers. The current study found similar
rates of parent endorsed impairment (e.g., 20 percent); however the current study further
contextualizes this finding, as this rate was not different than rates of impairment in healthy
controls.
Cancer survivors demonstrated performances on neurocognitive measures, including
both verbal and nonverbal reasoning, and executive functioning domains (i.e., attention,
verbal fluency, working memory, set-shifting, and planning) comparable to healthy controls.
This finding was contrary to our original hypothesis and is highly inconsistent with previous
findings, as extant research has found that cancer survivors demonstrate notable impairments
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in neurocognitive functioning (Campbell et al., 2008; Robinson et al., 2010). Cancer
survivors have been found to be particularly vulnerable to EF deficits, as performance has
generally been impaired by one standard deviation based on normative comparisons (Hile et
al., 2014; Peterson et al., 2008). One explanation for these null findings is that pediatric
cancer survivors demonstrate strong resiliency that is not completely understood and
therefore not considered in the context of the current study. Some of these factors related to
reliliency may include family and peer dynamics characterized by an increase in support
systems at home and academically.
Objective two: Neurocognitive functioning predicts FI. The purpose of this
objective was to characterize the relationship between neurocognitive functioning and
functional impairment more broadly, as well as explore this relationship within cancer
survivors relative to healthy controls. While previous research regarding this broad
relationship is limited, a theoretical basis has been well established. Additional research is
also favorable and has established a relationship between general intellectual functioning,
executive functioning, and more broad functional activities such as academic achievement,
social competence, and employment (Blair, 2002; Espy et al., 2004; Hughes, Dunn, & White,
1998). Additionally, previous research has identified cancer survivors as particularly
vulnerable for experiencing neurocognitive late effects (Moleski, 2001; Moore, 2008). These
two independent findings are the driving force for examining the impact of neurocognitive
deficits on more broad impairments in salient daily activities.
With regard to child self-reports of FI, preliminary and exploratory bivariate
correlations found a significant relationship between verbal reasoning and impairments in
interpersonal, self-care/self-fulfillment, and more global impairment. There was also
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evidence of a relationship between additional EF measures (e.g., verbal fluency, set shifting,
and working memory) and self-care/self-fulfillment. The directionality of these relationships
suggested that higher neurocognitive performances were related to lower impairment scores.
When all neurocognitive variables were included in a model predicting FI, only
verbal reasoning accounted for a significant amount of variance in the domains of functional
impairment, while planning abilities accounted for a significant amount of variance
specifically in school functioning.
However, the degree to which neurocognitive functioning predicted functional
impairment was different in cancer survivors relative to healthy controls. In cancer survivors,
verbal reasoning was a more robust predictor and accounted for a significant amount of
variance in global impairment (i.e., 36 percent); however, in healthy controls verbal
reasoning accounted for only three percent of the variance. A similar pattern emerged with
respect to verbal reasoning and school impairment. Generally speaking, the slope values
demarcating the relationship between neurocognitive functioning and FI were much steeper
and more robust in cancer survivors. This suggests that for cancer survivors, neurocognitive
functioning is related to broad functional impairment to a greater degree than the degree
demonstrated for healthy controls.
Findings were somewhat discrepant when parent reports of functional impairment
were examined in relation to neurocognitive functioning. When considering the relationship
more broadly (e.g., collapsed across groups), general intellectual functioning was
significantly related to school functioning, and higher IQ scores were related to lower school
impairment. However, this was the only notable finding. While verbal fluency and child
planning abilities were related to impairment, this was not in the expected direction. While a

57
relationship was established between neurocognitive functioning and FI per parent report,
these variables did not account for a significant amount of variance in parent report of
functional impairment.
While there were no main effect findings, a significant two-way interaction emerged
similar to what was found with respect to child self-reports. In cancer survivors, verbal
reasoning was more predictive of impairments in global impairment and self-care/selffulfillment when compared with healthy controls.
Taken together, these findings suggest neurocognitive functioning is significantly
related to broad daily functioning, but only in cancer survivors. This was consistent
regardless of reporting source (e.g. child vs. parent). This finding is particularly notable
given that, in this sample, cancer survivors did not demonstrate significant deficits in
neurocognitive functioning, and performances were comparable to healthy controls. So,
while cancer survivors did not demonstrate explicit deficits in neurocognitive functioning
relative to healthy controls, their neurocognitive status significantly predicted their broad
daily functioning.
While current findings are not consistent with previous research, it has been well
established that cancer survivors are more vulnerable to cognitive deficits following pediatric
cancer treatment (Campbell et al., 2008; Robinson et al., 2010), which has been linked to
structural changes in the brain (Zeller et al., 2013). Given the notable structural changes
within the central nervous system, cancer survivors may be more vulnerable to the functional
impact of those neurocognitive deficits, as they have fewer resources and less cognitive
reserve to buffer or compensate for the impact of neurocognitive abilities on their daily
activities. Conversely, this relationship may reflect one of resiliency, wherein cancer
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survivors who demonstrate intact neurocognitive functioning are then able to draw more
from this resource to influence and bolster their daily functioning, while healthy controls do
not need to rely so heavily on their neurocognitive status.
Objective three: Treatment, survivorship length, and cortisol predictors. The
purpose of objective three was to examine the impact of chronic stress, as measured through
hair cortisol levels, on neurocognitive and functional endpoints. The purpose was also to
examine this in conjunction with other established risk factors, primarily treatment severity.
While cortisol levels were slightly higher in cancer survivors relative to healthy controls, the
difference was not significant; however, children who experienced more intensive and severe
treatments also tended to demonstrate higher levels of cortisol. There was also a significant
relationship between length of survivorship and school functioning, such that longer
survivorships were associated with more impairment per parent report. This could potentially
be explained by an increase in academic expectations as the child moves farther away from
their initial treatment and diagnosis. As expectations increase, parents may observe a
growing gap between the academic expectations and the child’s abilities. Additionally,
previous research also suggests that neurocognitive late effects are slow to emerge, as they
manifest progressively over time (Annett et al., 2014; Spiegler et al., 2004).
While there were no main effect findings regarding the relationship between cortisol
and neurocognitive functioning, there was a significant group by cortisol interaction in
relation to verbal reasoning. In cancer survivors, higher cortisol levels were related to higher
verbal reasoning scores; however, this relationship was non-significant. In healthy controls,
the findings were in the opposite direction, such that lower cortisol concentrations were
associated with higher verbal reasoning scores. Again, this relationship was non-significant.
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A similar interaction was demonstrated in additional neurocognitive outcome measures
including sustained attention, as well as set shifting. Taken together, these findings suggest
that higher cortisol levels were related to better neurocognitive performances in the specific
domains of verbal reasoning, sustained attention, and set-shifting; whereas in healthy
controls, lower cortisol levels were related stronger neurocognitive performances.
The differential relationship between cortisol and neurocognitive performance has
been previously documented in the literature. For example, a complex relationship between
cortisol levels and neurocognitive functioning has been established, specifically in animal
models. This relationship has been found to follow a dose dependent relationship, such that
moderate levels of cortisol produce the most optimal cognitive functioning, while extreme
levels of cortisol (e.g., too high or too low) result in more impaired functioning (de Kloet et
al., 1999; Joels, 2006). Additional research even suggests that the timing of cortisol exposure
can determine whether it promotes or hinders cognitive functioning (Het, Ramlow, & Wolf,
2005). Results from the current study suggest that the relationship between cortisol and
neurocognitive performance may be even more complex, as different groups, primarily
cancer survivors, may respond differently to cortisol levels. However, there was no evidence
to suggest that survivorship impacted cortisol levels, as survivors demonstrated cortisol
levels comparable to healthy controls.
One proposed model of stress and cognition suggests that optimal cognitive
functioning occurs in the context of mildly elevated glucocorticoids (Diamond et al., 1992).
Given structural and functional changes in the CNS following pediatric cancer, it may be that
even higher levels of cortisol are necessary for optimal cognitive functioning in cancer
survivors relative to healthy controls.
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In sum, there were no differences in neurocognitive performances or functional
impairment in pediatric cancer survivors relative to healthy controls. Broadly speaking,
verbal reasoning was the most strongly associated with impairments across both groups;
however, for cancer survivors, the relationship between verbal reasoning and functional
impairment was much stronger. Treatment severity was unrelated to neurocognitive
functioning and broad functional impairment, which was inconsistent with study hypotheses.
However, treatment severity was related to cortisol. Finally, the effect of cortisol on
neurocognitive performance was different for cancer survivors relative to healthy controls, as
cancer survivors appeared to have a different association between neurocognitive
performance and cortisol levels relative to healthy controls.
Implications
First, findings from the current study suggest that there are significant differences in
how children and parents perceive and report on child functional impairments. This has
significant implications for how we assess and measure impairment both clinically and in
future research. Rates of clinically significant functional impairment, as self-reported by
children were more than two times higher than rates of impairment as reported by parents.
This represents a significant discrepancy and suggests error in current assessment techniques.
In particular, the continued use of self-report or parent-report measures as the sole means of
assessing impairment is not adequate. Instead, these findings speak to a need to access
additional sources of information, such as teacher reports and behavioral observations, as
well as develop more objective and standardized formal performance based measures.
Second and most notably, cancer survivors did not demonstrate deficits in
neurocognitive functioning. They also did not demonstrate more pronounced functional
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impairments relative to healthy controls. While the current study found rates of clinically
significant functional impairment similar to those found in our previous study with a
different sample (Hile et al., 2014), these rates did not differ significantly from healthy
controls. Overall, this suggests that despite toxic and aggressive treatment protocols,
prolonged hospital stays, and absences from school and peer activities, pediatric cancer
survivors are not necessarily at higher risk for reporting functional impairments than the
general population. This then may speak to underlying resilience factors in pediatric cancer
survivors that should be further explored in future research. Current study findings suggest
that verbal reasoning may represent a specific resilience factor, as well as optimal levels of
stress.
However, previous and current research paradigms invoke a deficit model, as
research has been primarily concerned with identifying, characterizing, and predicting
deficits within pediatric cancer survivors. In contrast to this model, current findings suggest
that examining resilience, as well as variables that predict and promote resilience may also be
particularly relevant in understanding the nature of pediatric cancer survivorship, as well as
understanding how to promote improvements in survivors’ quality of life.
Although cancer survivors reported rates of functional impairment comparable to
healthy controls, these findings occurred within the context of lower treatment severity
scores. Therefore, these findings can only be generalized to the sample of pediatric cancer
survivors that have been exposed to lower levels of or no CNS directed treatments. It should
also be noted that performances on intellectual and executive functioning tasks were also
comparable to healthy controls. This is largely inconsistent with a substantial body of
research that finds notable deficits in neurocognitive functioning approximately one standard
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deviation lower than the normative sample (Hile et al., 2014; Campbell et al., 2008;
Robinson et al., 2010). Given this, it may be that the normal range performances on
neurocognitive measures may have been driving the low rates of functional impairment. This
is further supported by additional findings indicating that verbal reasoning abilities
significantly predicted functional impairment, a finding that was particularly robust in cancer
survivors. Therefore, given their normal range performances on neurocognitive measures, it
is less surprising that cancer survivors did not demonstrate higher rates of FI. Taken together,
this suggests that resilience may be related to neurocognitive functioning, and verbal
reasoning in particular may serve as a buffer or a protective factor against more global
impairments.
Cancer survivors may also be more vulnerable to the impact of neurocognitive
deficits on global functioning. This finding has significant implications regarding
survivorship care and management of late effects, as well as highlights the need for
neuropsychological assessments and even brief neuropsychological screenings. This can help
inform and discern risk and resilience with regard to broader daily functioning, as well as
identify the need for additional accommodations and services to help address cognitive and
functional impairment findings.
Finally, while previous research in childhood chronic illness populations has
suggested a relationship between increases in parental stress and poor overall child outcomes
(Chaney et al., 1997; Davis et al., 2001; Thompson, Gil, Burback, Keith, & Kinney, 1993),
this finding appears to be specific to self-reported parental stress. With regard to child stress,
pediatric cancer survivors who demonstrated higher chronic stress, as indexed by hair
cortisol, were not more likely to demonstrate impairments in neurocognitive functioning or
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broad functional impairment. In fact, the opposite relationship was demonstrated, as higher
cortisol levels were associated with better performance on intellectual and executive
measures. However, this was only true for cancer survivors and not healthy controls. Given
this, it may be that slightly elevated stress levels may be optimal for cognitive functioning
and may represent another protective factor for cancer survivors. Future research should
further examine chronic stress and stress reactivity in relation to neurocognitive and
functional outcomes, as well as investigate the directionality of the relationship. This has
important implications for how we perceive stress both clinically and in future research, as
stress has generally been examined in relation to iatrogenic effects.
Limitations and Directions for Future Research
This study represents a rather novel approach to the study of late effects in pediatric
cancer survivors. As such, there were many limitations to the study and many directions in
which future research may proceed.
First, a selection bias is possible and recruitment strategies may not have yielded an
accurate representation of pediatric cancer survivors as a whole. The low recruitment rate of
cancer survivors (24 percent) speaks to the possibility that cancer survivors who agreed to
participate differed systematically from those who were approached but declined
participation. This is further supported by the current study finding that cancer survivors did
not demonstrate more deficits in executive and intellectual functioning relative to healthy
controls, which is highly inconsistent with extant research. This discrepant finding suggests
that the current sample may not have been representative of the broader population of
pediatric cancer survivors.
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The possibility of a selection bias was evaluated to the extent that relevant variables
were made available for non-participants. Non-participant data were limited to child sex, age,
and diagnosis. Based on these variables, males were more likely to decline participation than
females, indicating that female cancer survivors were overrepresented in the study sample,
while males were underrepresented. There were no significant differences in age and
diagnosis across participants and non-participants. However, there were additional variables
that may have affected study participation that were not evaluated including SES and
location of residence (e.g., rural vs. urban).
The current study procedures placed high demands on potential participants and their
families, as participants were required to return to a different location on a different
scheduled day, which often required significant travel time. Additionally, study procedures
ranged from 1-2 hours. The ability to participate in study procedures may have been difficult
for families with limited resources (e.g., lower SES) and for families who lived in more rural
areas in which travel time was extended. Additionally, the ability to participate in study
procedures may also have been more difficult for families with children with cognitive and
functional impairments. Given this, it may be that cancer survivors who were willing and
able to participate in study procedures were systematically different, perhaps reflecting
higher SES and lower overall impairments. Future research should include modified study
procedures so as to lessen the potential demands on families in order to increase recruitment
rates and reduce the possibility of a selection bias.
Another limitation involves the low concordance rates between parent and child
reports of child functional impairment and the tendency for children to report significantly
higher levels of impairment relative to parents. The lack of consistency across informant
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reports begs the question of whether the construct of functional impairment was accurately
assessed, suggesting underlying issue with construct validity. In particular, the reliability and
validity of the child version of the BIS was questionable given the lower internal consistency
score relative to the adult version. This was the first attempt to extend a parent self-report
measure to children, which may account for lower internal consistency scores. Additionally,
there were a surprisingly large percentage of children who endorsed clinically significant
impairment. Approximately half of children, including both cancer survivors and healthy
controls, endorsed clinically significant levels of functional impairment. These rates are
much higher than rates found in both clinical and community samples. One hypothesis was
that younger children demonstrated poorer insight and understanding of questions, which
may have driven the elevated rates. However, further analyses examining mean scores on the
BIS across younger and older children did not support this hypothesis. At this point it is
unclear as to why children endorsed higher rates of impairment relative to their parents;
however, it is clear that further research is needed to develop a psychometrically sound
measure of functional impairment completed by children. As noted above, future research
should also work to develop more objective and reliable measures of functional impairment
using both observational methods and informant reports.
Additionally, while the combined sample size was sufficient to achieve adequate
power (.80), given the relatively small sample size, the specific data analytic techniques were
limited and additional variables of interest were excluded from the tested models, particularly
within models of pediatric cancer survivors. These variables included gender, age at
diagnosis, occurrence of relapse and transplant.
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The current study helped to determine the feasibility of implementing this particular
research design within a clinical sample. As noted above, future research could modify the
design so as to lessen the participant burden and increase sample size so additional variables
of interest can be included in the model. This will help determine the relative contribution of
chronic stress and treatment and illness related variables on the presentation of
neurocognitive and functional deficits. Additionally, a larger sample size would also allow
for the examination of additional resiliency factors and their impact of neurocognitive and
functional outcomes. This would also allow for a more detailed characterization of the
relevant relationships including mediating and moderating relationships. Although research
is rather limited in this area, one study found that illness related variables, including
diagnosis and length of treatment, were unrelated to resiliency. However, environmental
factors, such as family cohesion, teacher support and positive peer relationships, were highly
predictive of resilience (Kim and Yoo, 2010). Given this, future research should include
environmental and family factors in developing a comprehensive model of outcomes
associated with the pediatric cancer experience.
Additionally, while future research should continue to identify risk and resilience
factors, additional research should also determine their impact on intervening brain structures
and how that relates to neurocognitive and functional outcomes.
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Conclusion
In sum, this study represents a novel approach to the study of neurocognitive late
effects in pediatric cancer survivors by providing evidence in favor of a relationship between
neurocognitive performance and broad functional impairment, as well as characterizing the
relationship between other risk factors and neurocognitive and functional outcomes. This
offers a new perspective to the study of late effects by helping to quantify the functional
impact of neurocognitive deficits, as well as identify associated risk factors. Associated risk
factors included treatment and illness related factors, as well as chronic stress measured
through hair cortisol.
Overall, there were no differences in neurocognitive performances or reports of
functional impairment in pediatric cancer survivors relative to healthy controls. Verbal
reasoning was the neurocognitive measure most highly associated with broad Functional
Impairment; however, this was only true in cancer survivors. With regard to illness and
treatment related variables, there was a significant relationship between length of
survivorship and school impairment. Additionally, treatment severity was related to cortisol
levels. Cortisol was not significantly associated with neurocognitive functioning or FI;
however, there was a significant interaction such that cancer survivors appeared to benefit
from higher cortisol levels. Conversely, healthy controls appeared to benefit from lower
cortisol levels. However, this study is only a pilot study and more research needs to be done
to provide further information regarding the proposed model, as well as explore additional
risk and resiliency factors.
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Figures

Figure 1: Conceptual Model of Neurocognitive Late Effects.	
  A theoretical model of the
neurocognitive late effects of pediatric cancer. Solid lines represent established relationships,
while dotted lines represent relationships that have not yet been characterized within
pediatric cancer populations and will be examined within the current study.
Note: CNS structural changes is included within the theoretical model given the significant
empirical evidence; however further exploration of the relationship between CNS structural
changes and other variables characterized within the model remains outside the scope of the
current study and should be included in future research
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Figure 2: Group by Verbal Reasoning Interaction on BIS-CV Scores
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Figure 3: Group by Verbal Reasoning Interaction on BIS-CV School Scores
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Figure 4: Group by Verbal Reasoning Interaction on BIS-P Total Scores
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Figure 5: Group by Verbal Reasoning Interaction on BIS-P Self-Care Scores
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Figure 6: Group by Cortisol Interaction on Verbal Reasoning T Scores
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Figure 7: Group by Cortisol Interaction on NIH Examiner CPT Scores
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Figure 8: Group by Cortisol Interaction on NIH Examiner Set Shifting Scores
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Tables
Table 1: Demographic Characteristics
Variable

Cancer
(n=20)

Control
(n=41)

Significance
(p)

Child age (years)
SESb

11.55 (4.08)a
31.36 (11.35)a
N(%)

10.32(3.67)
37.59(11.56)
N(%)

0.24
0.054

Child ethnicity
0.25
White
6(30%)
9(22%)
Hispanic
9(45%)
18(44%)
Native American
2(10%)
1(2%)
Asian
1(5%)
0(0%)
Hawaiian/Pacific
0(0%)
1(2%)
Islander
Other
2(10%)
12(29%)
Gender
0.49
Female
14(70%)
25(61%)
Special Education
0.44
Yes
2(20%)
12(29%)
Cancer Diagnosis
Leukemia/Lymphoma
11(55%)
NA
LCH
2(10%)
NA
Aplastic Anemia
1(5%)
NA
Malignant Germ Cell
1(5%)
NA
Tumor
Wilm’s Tumor
2(10%)
NA
Ewings Sarcoma
1(5%)
NA
Rhabdomyosarcoma
1(5%)
NA
Neuroblastoma
1(5%)
NA
a
M(SD)
b
Barratt Simplified Measure of Social Status (BSMSS), higher values indicate higher SES
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Table 2: Parent-Child Concordance on the Brief Impairment Scale

Parent Reportb

Total
Impairment
0.27*
0.24
0.24
0.16

Child
Reporta
Interpersonal

School

Self-Care/SelfFulfillment
0.06
-0.01
-0.05
0.23

Total
0.12
0.38**
Interpersonal
0.18
0.34**
School
0.09
0.41**
Self-Care/Self0.01
0.16
Fulfillment
*p <0.05, ** p<0.01
a
Brief Impairment Scale-Child Version adapted from Bird et. al., (2005)
b
Brief Impairment Scale (Bird et al., 2005)

Table 3: Brief Impairment Scores Across Cancer Survivors and Healthy Controls
BIS score
Parent reporta
Total score
% Above clinical
cutoff
Interpersonal
School
Self
Child reportb
Total score
% Above clinical
cutoff
Interpersonal
School
Self
a

Cancer M (SD)

Control M (SD)

T

Significance

8.25 (7.28)
20%

7.18 (5.66)
13%

0.635

0.53

2.26(3.21)
3.25(3.45)
2.62(2.25)

2.03(2.03)
2.30(2.45)
2.84(2.85)

0.34
1.25
-0.35

0.73
0.23
0.73

15.38(8.87)
45%

14.04(5.91)
46%

0.69

0.49

5.51(4.09)
4.3(3.60)
5.33(2.96)

5.40(3.80)
3.62(2.71)
5.05(2.62)

0.10
0.80
0.37

0.92
0.43
0.71

Brief Impairment Scale (Bird et al., 2005)
Brief Impairment Scale-Child Version adapted from (Bird et. al., 2005)

b
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Table 4: IQ Scores Across Cancer Survivors and Healthy Controls
IQ Scorea

Cancer M (SD) Control M (SD)

T

Significance

Full Scale IQ
99(12.65)
98(12.97)
0.41
0.69
Verbal IQ
46(10.89
45(12.11)
0.45
0.65
Non-Verbal IQ
52(9.38)
52(10.13)
0.09
0.93
a
The Reynolds Intellectual Screening Test (RIST; Reynolds & Kamphaus, 2003).

Table 5: EF Scores Across Healthy Controls and Cancer Survivors
NIH Examinera

Cancer M(SD)

Verbal Fluency
24.80(9.12)
Planning
0.49(0.21)
Continuous Performance 94(8.17)
N Back Task
0.54(2.93)
Set Shifting
6.97(1.27)
a
NIH Examiner (Kramer et al., 2014)

Control M(SD)

F

Significance

22.02(9.40)
0.37(0.18)
89(21.5)
0.28(2.81)
5.92(3.35)

0.19
0.10
0.36
0.25
0.81

0.67
0.76
0.55
0.62
0.37
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Table 6: Pearson Bivariate Correlations Collapsed Across Groups

Neurocognitive
Measures
IQb
Full Scale IQ
Verbal IQ
Nonverbal IQ
EFc
Verbal Fluency
Planning
Set-shifting
N-Back
Continuous
Performance

Total

BIS scales
(Child)d
Interpersonal

School

Self Care

-0.36**
-0.38**
-0.09

-0.28*
-0.26*
-0.08

-0.18
-0.15
-0.11

-0.30*
-0.39**
-0.03

-0.18
0.23
-0.09
-0.11
0.02

-0.21
0.20
-0.13
-0.11
-0.01

0.15
0.31*
0.23
0.16
0.11

-0.32*
-0.04
-0.28*
-0.33*
-0.08

BIS scales
(Parent)a
Interpersonal

Neurocognitive Total
School
Self Care
Measures
IQb
Full Scale IQ
-0.24
-0.08
-0.29*
-0.21
Verbal IQ
0.74
0.15
-0.01
0.04
Nonverbal IQ -0.21
-0.09
-0.22
-0.21
EFc
Verbal Fluency 0.26*
0.39**
0.14
0.07
Planning
0.16
0.26*
-0.02
0.17
Set-shifting
0.07
0.15
-0.01
0.04
N-Back
0.18
0.28
0.02
0.13
Continuous
-0.02
0.04
-0.02
-0.08
Performance
*p <0.05, ** p<0.01
a
Brief Impairment Scale (Bird et. al., 2005)
b
The Reynolds Intellectual Screening Test (RIST; Reynolds & Kamphaus, 2003).
c
NIH Examiner (Kramer et al., 2014)
d
Brief Impairment Scale Child version adapted from (Bird et al., 2005)
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Table 7: Pearson Bivariate Correlations within cancer survivors
BIS scales
(Child)d
BISInterpersonal

BISSchool

BIS-Self
Care

-0.49*
-0.55*
-0.21

-0.42
-0.37
-0.23

-0.37
-0.48*
-0.14

-0.41
-0.50
-0.16

-0.04
0.25
-0.14
-0.19
-0.08

0.17
0.27
-0.25
-0.10
-0.12

0.16
0.27
0.13
0.01
0.07

-0.33
0.12
-0.39
-0.42
-0.17

BIS scalesa
(Parent)
BISInterpersonal

BISSchool

BIS-Self
Care

-0.24
-0.18
-0.21

-0.08
-0.05
-0.09

-0.29*
-0.21
-0.22

-0.22
-0.18
-0.21

0.26*
0.16
0.07
0.03
-0.02

0.39**
0.26*
0.15
0.12
0.04

-0.14
-0.02
-0.01
-0.03
-.02

-0.07
0.18
0.04
-0.04
-0.08

Neurocognitive
Measures
IQb
Full Scale IQ
Verbal IQ
Nonverbal IQ
EFc
Verbal Fluency
Planning
Set-shifting
N-Back
Continuous
Performance

BIS-Total

Neurocognitive
Measures
IQb
Full Scale IQ
Verbal IQ
Nonverbal IQ
EFc
Verbal Fluency
Planning
Set-shifting
N-Back
Continuous
Performance

BIS-Total

*p <0.05, ** p<0.01
a
Brief Impairment Scale (Bird et. al., 2005)
b
The Reynolds Intellectual Screening Test (RIST; Reynolds & Kamphaus, 2003).
c
NIH Examiner (Kramer et al., 2014)
d
Brief Impairment Scale Child version adapted from (Bird et al., 2005)

79
Table 8: Descriptive Statistics across Cancer Treatment Severity, Survivorship, and Cortisol
Cancer variables

Cancer M(SD)

Control M(SD)

Treatment severity

1.21(1.03)

n/a

n/a

Length of Survivorship

6.17(2.38)

n/a

n/a

Cortisol (ug/dl)

15.97(7.44)

13.64(7.40)

F

1.102

Significance

0.299
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